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Chapter 1
General introduction and aims.





Chronic kidney disease is a major health burden affecting millions of people worldwide. 
End-stage renal disease (CKD5, eGFR <15 ml/min) has an estimated global prevalence 
of 0.1% (1). Kidney transplantation is the preferred choice of treatment for patients 
with end-stage renal disease. Kidney transplantation requires an elaborate medical 
infrastructure. Even in countries with well-developed deceased donor and living donor 
transplant programs, access to transplantation is not ubiquitous. For example in the 
Netherlands only two-thirds of patients on renal replacement therapy have a functioning 
kidney allograft (2). Barriers to kidney transplantation are medical conditions in the 
recipient, shortage of donor organs and circulating antibodies against potential donors. 
These antibodies can be directed against HLA molecules on nucleated cells, non-HLA 
(endothelial) antigens and against targets on red blood cells. Clinically the most relevant 
red blood cell antigens are those from the ABO blood group system. Incompatibility in 
ABO blood group between donor and recipient can cause life-threatening hemolysis 
after blood transfusion. Blood group A and B antigens are not only expressed on red 
blood cells, but also on endothelial, tubular and glomerular cells (3). Therefore anti-ABO 
antibodies are highly relevant in kidney transplantation. Not accounting for different 
blood groups between the kidney allograft and the recipient may cause hyper-acute 
rejection of the graft.
The ABO blood group system
Red blood cells carry numerous sugars and proteins on their surface that are antigenic 
in other humans. These molecules have various functions ranging from structural, 
channel and transport functions to complement regulation and infection prevention 
(4). Polymorphisms in red blood cell antigen can result from natural selection. For 
example the Duffy glycoprotein, involved in clearing inflammatory cytokines, has a 
West African Duffy variant phenotype Fy (a-b-) that protects the red blood cell from 
malarial invasion (5). Red blood cell antigens are categorized in 29 blood group systems 
according to the different encoding genes. Of these, the ABO blood group system is the 
most notable, for its relevance in transfusion medicine due to the immunogenic nature 
of its antigens. The different blood groups A, B, AB and O result from the inherited 
activity of glycosyltransferase enzymes encoded by the ABO gene. People with blood 
group O express the α-1,2-fucosyltransferase enzyme that forms an α-l-fucose to 
α-d-galactose carbohydrate backbone bound to glycolipids or proteins, named the H 
antigen. In people with blood group A, α-1,3-n-acetylgalactosaminyltransferase attaches 
β-N-acetylgalactosamine (the A antigen) to this H backbone. There are two different 
tranferases expressing either low or high amounts of A antigen: A1 individuals are high 
expressers and A2 individuals (20% of blood group A) are low expressers. People with 
blood group B express on their H antigen D-galactose (the B antigen) under the influence 
of the enzyme α-1,3-galactosyltransferase, while blood group AB individuals express 
both sugars as depicted in Figure 1 (6).
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Figure 1. The structure of ABO surface antigens and their corresponding antibodies. Reprinted with 
permission from reference 6: Böhmig, Nat. Rev. Nephrology 2015 (6).
1
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The function of the ABO polymorphisms is not fully understood. Blood group 
distribution varies by ethnicity. A remarkable finding is that blood group O individuals 
have 25% lower levels of Von Willebrand factor than the other ABO types, and are 
overrepresented in heavy menstrual bleeding and post-tonsillectomy hemorrhage (7), 
with a relative protection against venous thrombosis (8, 9).
The ABO blood group system is also defined by the presence or absence of antibodies 
that can agglutinate blood, as discovered by Karl Landsteiner in 1901. ABO-antibodies 
are absent at birth. During infancy, when the gut becomes colonized with bacteria, 
”isoagglutinin” formation starts as a result of similarities in bacterial antigens and blood 
group AB antigens. Auto-antibodies are eliminated leaving O individuals with anti-AB 
antibodies, B individuals with anti-A antibodies, A individuals with anti-B antibodies 
and AB individuals without any AB isoagglutinins (10). These isoagglutinins are the 
source of serious hemolytic transfusion reactions in transfusion medicine. In solid 
organ transplantation, non-ABO-identical transplantation can elicit immune responses, 
because AB antigens are also expressed on other cell types. Because AB antigens are 
present on parenchymal and vascular kidney cells, anti-A/B antibodies directed against 
the allograft can result in antibody-mediated rejection in ABO-incompatible kidney 
transplantation. There are many other blood group systems including Duffy, Kidd and 
Rhesus. Although the last-named system is highly relevant for avoiding immunization 
in obstetrical care, it is less relevant for solid organ transplantation as renal cells do not 
express the Rhesus antigens. Rarely, mismatches for minor blood group systems are 
related to acute rejection of the transplanted kidney (11).
ABO blood group and kidney transplantation
Blood group O donors are “universal donors” (lacking A and B antigens) because they are 
compatible with any blood group of the recipient. Vice versa blood group O recipients 
(with A/B antibodies) are only compatible with blood group identical donors (blood 
group O donors). Blood group distribution varies by population. A random recipient 
donor combination will be blood group incompatible in roughly one out of three cases. 
In the Dutch population, blood group O candidates are compatible with approximately 
47% of potential donors (12). Blood group AB individuals are “universal recipients” 
and compatible with any potential donor. Blood group O candidates have less access 
to kidney transplantation when kidney allografts are allocated in an ABO-compatible 
manner instead of an ABO-identical manner. Deceased donor kidneys are mostly 
allocated by Eurotransplant in a blood group identical manner (standard ETKAS and 
senior programs). However, a minority of approximately 5% of kidneys is allocated via 
the Acceptable Mismatch program in a blood group compatible program to prioritize 
the highly immunized candidates (13). In the living donor programs the vast majority 
of donations are directed and therefore blood group compatible. The allocation in 
living donation programs therefore disadvantages blood group O candidates. In 2012, 
42% of the Dutch population had blood group O, as against 41% in the recipients of 
a deceased donor kidney allograft and only 33% in recipients of a living donor graft 
AnneliesdeWeerd_bnw.indd   10 8-2-2021   10:34:17
11
Introduction
(14). This relatively low percentage existed despite operational ABO-incompatible 
and exchange programs and remains a problem today. In 2018, 57% of all Dutch 
patients actively waiting for a donor kidney had blood group O (408/719 (13)). Of all 
transplanted deceased donor kidneys 49% were blood group O, whereas in the living 
donor recipients 38% had blood group O (13). These numbers underlie the importance 
of optimal allocation rules and underscore the clinical need for ABO-incompatible 
transplantation.
History of ABO-incompatible kidney transplantation
During the pioneering years of the first relatively successful human kidney transplantations 
in the 1950s, ABO blood group incompatibility was deemed a risk for hemolysis in the 
allograft. In the 1960s, the experiences of Starzl et al. led to the perception that blood 
group violation could also cause rejection of the allograft (15). In Figure 2 his findings in 
a series of 16 kidney allograft recipients led to Starzl’s reflections on the safety of ABO-
incompatible (ABOi) kidney transplantation that still hold true today.
Figure 2. This series of 16 non-ABO-identical kidney transplant recipients led to Starzl. et al.‘s speculations 
on the safety of ABO-incompatible kidney transplantation. Reprinted with permission from reference 15: 
Starzl, Surgery 1964 (15).
1
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For decades, the presence of ABO antibodies against the blood group of the donor was 
considered an absolute contra-indication for kidney transplantation. However, as this 
ABO barrier severely limited the pool of donor organs available for O recipients, and not 
all unintended ABOi transplantations had a deleterious course, interest in overcoming 
ABO barriers never faded (16). In the early 1980s, Alexandre and colleagues pioneered 
ABOi kidney transplantation in Belgium (17). A desensitization treatment was developed 
consisting of three elements: removal of circulating antibodies, inhibition of antibody 
production and immunosuppression to inhibit immune responses. Plasmapheresis, 
splenectomy, infusion of donor platelets and immunosuppression were used to 
desensitize these ABOi allograft recipients preoperatively (18). ABOi transplantation 
was further disseminated in Japan and the USA (19, 20). Modifications made to the 
desensitization treatment in Japan were local graft irradiation and plasmapheresis with 
or without immunoadsorption. The “gamechanger” in ABOi kidney transplantation 
was the introduction of rituximab (21). This anti-CD20 monoclonal antibody made 
splenectomy an obsolete procedure (22). Rituximab and immunoadsorption have been 
the cornerstones of ABOi kidney transplantation in Europe from the early 21st century 
onwards. It is now considered a safe procedure, accounting for approximately one fourth 
of living procedures in some centers in Germany and Japan. Its contribution to kidney 
transplantation procedures depends on the elaboration of living-donor programs, 
the presence of kidney exchange programs and the availability of desensitization 
treatments. In the Netherlands, the first ABOi kidney transplantation took place in 
2006 at the Erasmus Medical Center (MC). The applied desensitization treatment 
was launched by Tyden et al. in Stockholm (23). This “Swedish” protocol consisted 
of rituximab, selective immunoadsorption (with an A/B antigen-specific adsorption 
column), IVIG (intravenous immunoglobulins) and immunosuppression preoperatively 
(23, 24). Subsequent adaptations of the Erasmus MC protocol consisted of the 
discontinuation of postoperative plasmapheresis and change in the induction agent 
from B-cell depletion to combined T- and B-cell depletion. Randomized controlled trials 
are lacking in ABOi kidney transplantation and novel therapies have been launched and 
modified in pioneering centers. Desensitization elements have been selectively adapted 
according to patients’ characteristics (such as age and blood group titers) and single 
center experiences. A difficulty in studying ABOi kidney transplantation is to define an 
appropriate comparator: should ABOi candidates be compared to dialysis, deceased 
donor transplantation with or without waiting list time, other types of desensitization 
treatment or living donor blood group compatible transplantation? 
The nature of A/B antibodies, at the center of desensitization protocols, is not fully 
understood. The damage caused by circulating A/B antibodies differs from the (in general 
more deleterious) effect of anti-HLA antibodies (25, 26). Ligation of A/B antibodies to 
endothelial cells has been demonstrated to induce different signaling pathways than 
HLA-antibodies in experiments with endothelial cell line expressing A/B antigens (27). 
Interaction of A/B antibodies with vascular cells inhibited the ERK1/2 (extracellular 
signal-regulated kinases) pathway, resulting in an increase in complement regulatory 
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proteins via the induction of CD55 and CD59. This led to the acquired resistance of 
the endothelial cells to complement-mediated cytotoxicity in these experiments. This 
could be an explanation for the frequent finding of C4d deposition in biopsies of ABOi 
kidney allografts without clinical signs of antibody-mediated rejection. This apparent 
accommodation of A/B antibodies without graft injury, is a key concept in ABOi kidney 
transplantation. Lower A/B antigen expression over time in the ABOi donor kidney 
versus stable A/B antigen expression in the ABO-compatible (ABOc) donor allograft, 
as well as blood-type chimerism in the renal endothelium, have also been described 
(28). This apparent accommodation that may exist in the allograft in the presence of 
A/B antibodies questions target titers perioperatively.
The overall aim of this thesis is to improve outcomes for kidney transplant candidates 
who are blood group incompatible with their potential donor. It includes clinical studies 
in the Erasmus Medical Center as well as in national and international patient cohorts, 
with the following aims:
AIMS OF THE THESIS
1. To weigh the risk of ABOi kidney transplantation by comparing patient and death-
censored graft survival in a meta-analysis, including all single center studies 
comparing ABOi and (matched) ABOc kidney transplant recipients (chapter 2).
2. To analyze the results of the first cohort of 50 ABOi kidney transplant recipients 
in the Erasmus Medical Center Rotterdam, in order to evaluate the Swedish 
desensitization protocol (chapter 3).
3. To explore the clinical observation of a higher bleeding risk after ABOi kidney 
transplantation and to study its underlying mechanisms (chapter 4).
4. To study the relation between postoperative A/B antibody titers and rejection, in 
order to clarify the need for postoperative immunoadsorption (chapter 5).
5. To analyze the national cohort of ABOi kidney transplant recipients by comparing this 
cohort with propensity matched blood group compatible living donor and deceased 
donor recipients, in order to establish the risk of desensitization and to gain clinical 
information for counseling incompatible donor-recipient pairs (chapter 6).
6. To analyze outcomes of ABOi kidney transplantation according to different induction 
therapies, comparing rituximab single agent therapy to alemtuzumab and to 
rituximab/basiliximab induction therapy (chapter 6).
7. To explore the possible booster effect of a Gram-negative sepsis on A/B antibody 
formation, by studying a recipient in whom a Serratia marcescens sepsis preceded 
a fulminant antibody-mediated rejection (chapter 7).
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ABO-incompatible kidney transplant outcomes: 
A meta-analysis.
How safe is crossing the ABO blood group 
barrier?
Annelies E de Weerd, Michiel GH Betjes.
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1234-1243.
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ABO blood group-incompatible kidney transplantation is considered a safe procedure, 
with non-inferior outcomes in large cohort studies. Its contribution to living kidney 
transplantation programs is substantial and growing. Outcomes compared to center-
matched ABO blood group-compatible control patients have not been ascertained.
Design
Comprehensive searches were conducted in Embase, Medline, Cochrane, Web-of-
Science and Google Scholar. MOOSE study guidelines for observational studies and 
Newcastle Ottawa bias scale were implemented to assess studies. Meta-analysis 
was performed using Review Manager 5.3. A subgroup analysis on antibody removal 
technique was performed.
Results
After identifying 2728 studies addressing ABO-incompatible kidney transplantation, 26 
studies were included, describing 1346 unique ABO-incompatible patients and 4943 
ABO-compatible controls. Risk of bias was low (all studies ≥ 7/9 stars). Baseline patient 
characteristics revealed no significant differences in immunological risk parameters. 
Statistical heterogeneity of studies was low (I2 0% for graft and patient survival). One-
year uncensored graft survival of ABO-incompatible patients was 96% versus 98% in 
ABO-compatible controls (RR 0.97, CI 0.96-0.98, p<0.001). 49% of reported causes of 
death in ABO-incompatible patients were of infectious origin, versus only 13% in ABO-
compatible patients (p=0.02). Antibody-mediated rejection (3.86, CI 2.05-7.29, p<0.001), 
severe non-viral infection (1.44, CI 1.13-1.82, p=0.003) and bleeding (1.92, CI 1.36-2.72, 
p<0.001) were also more common after ABO-incompatible transplantation.
Conclusion
ABO-incompatible kidney transplant recipients have good outcomes albeit inferior to 
center-matched ABO-compatible control patients.
2




Desensitization protocols have allowed for successful transplantation of kidney 
allografts across the ABO blood group barrier. Pioneering centers in ABO-incompatible 
kidney transplantation have published patient and graft survival rates comparable to 
ABO-compatible transplantations (1-3). These reassuring outcomes combined with long 
waiting times for deceased donor kidneys and the shortage of available living donors 
have led to a broader implementation of ABO-incompatible transplantation. It accounts 
for one fourth of living donor transplantations in German centers (4, 5) and almost one 
third of procedures in Japanese centers (6, 7).
Therefore, a kidney transplant candidate with an ABO-incompatible living donor has 
options to wait for a deceased ABO-compatible donor (remain on dialysis), participate 
in a kidney exchange program (if operative) or proceed with desensitization for ABO-
incompatible transplantation. In order to ensure the ability to make an informed 
decision about which option to choose, the additive risk of desensitization for ABO-
incompatible donor-recipient pairs should be known.
Data on the potential additive risk of ABO-incompatible kidney transplantation have 
been deduced from registry and cohort studies. Recent cohort studies have shown no 
significant difference in graft and patient survival compared to ABO-compatible kidney 
transplantation (5, 8, 9). The largest registry study with ABO-compatible controls is 
from the Collaborative Transplant Study (10, 11). Three-year patient survival was not 
significantly lower, however there was more infection-related mortality. A registry study 
from Korea reported comparable graft survival rates, with a trend towards inferior 
patient survival (12). Registries from the United States revealed somewhat different 
results with more early graft loss and equal or inferior patient survival (13, 14), but these 
registries also contained splenectomized patients. A disadvantage of these registries 
is the uncertainty about completeness and quality of data, and inclusion of patients 
treated with different desensitization protocols, limiting external validity.
For these reasons we have performed a meta-analysis of single center cohort studies 
published with a control group consisting of ABO-compatible patients from the same 
hospital. Information from such a meta-analysis includes a large number of patients 
allowing the ability to identify risk differences in relatively rare events like patient death 
and graft loss across different desensitization regimes.
The primary objective of the meta-analysis was to compare the risk for graft and 
patient survival after ABO-incompatible versus ABO-compatible kidney transplantation. 
As secondary outcomes the differences in risk for acute rejection, infectious 
complications, and post-operative bleeding were analyzed.




We have performed the meta-analysis according to guidelines for observational studies 
as described in the MOOSE study (15).
Literature search strategy
Research database
The meta-analysis is a sequel of a systematic literature search to create an ABO-
incompatible research database. This original search was carried out in Embase, 
Medline, Cochrane, Web-of-Science and Google Scholar. The broad index terms are 
described in Supplemental Table 1, which identifies all studies on ABO-incompatible 
kidney transplantation published till July 1st 2017. Studies were screened for relevance 
to this database: eligibility criteria were medical aspects of kidney transplantation 
(excluding studies on financial aspects). A limitation was English language only and 
case reports were excluded. Search results were analyzed in Endnote. This database 
was built in Excel and categorized studies according to topic(s).
Meta-analysis
Next, studies in this database were screened for inclusion in the meta-analysis by two 
independent researchers, AdW and MB (both nephrologists). Eligible were all single 
center studies comparing ABO-incompatible patients with ABO-compatible controls 
reporting patient and graft survival. Conference abstracts were excluded. Reports 
usually define an era with splenectomy and a “modern” era with rituximab induction, 
with improved outcomes in the latter (7, 16). For this reason the older studies using 
splenectomy were excluded. Studies on combined HLA-incompatible and ABO-
incompatible transplantation were excluded, as were studies on deceased donor 
kidney allografts. The final step was to identify unique patients by excluding overlapping 
reports from the same center. Authors were contacted via email and ResearchGate to 
ask for missing data and (if available) for 3-year follow-up data.
Data collection and data items
The following items were identified in the included studies and reported in Excel:
Patients and controls: Patients were all living ABO-incompatible kidney transplant 
patients during the study period of the included study who were treated without 
splenectomy. Controls were either consecutive (all patients with a living ABO-
compatible kidney transplant during the study period) or matched according to the 
matching criteria of the included study (see quality assessment). In general, studies 
excluded HLA-incompatible transplantations from their analysis.
Immunoadsorption and plasmapheresis: There is no universal ABO-incompatible 
desensitization protocol and centers differ in immune suppressive therapy and 
isoagglutinin removal technique. For analysis, studies were divided into centers using 
(mainly) plasmapheresis versus (mainly) immunoadsorption.
2
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Baseline patient characteristics: number of patients, recipient and donor age, level 
of panel-reactive antibodies (PRA), donor-specific antibodies (DSA), percentage of 
retransplant and pre-emptive transplantations were recorded.
Uncensored-graft survival , patient survival: these outcome were deduced from Kaplan-
Meier survival curves and from numbers and percentages described in the results 
sections. Uncensored graft survival was established as follows: its numerator was 
determined by either graft loss or patient death and the denominator was the total 
number of patients censored for loss to follow-up.
Uncensored graft survival was determined for year one and if available year three. In 
case of availability of year three data, graft survival after year one was determined as 
follows: the numerator was graft survival at year three and the denominator was the 
number of patients censored for follow-up and censored for graft loss and patient 
death at year one.
Cause of death: infectious origin versus non-infectious origin (including unknown) 
causes of death were extracted from the included studies.
Biopsy-proven acute rejections included all (mainly year one) biopsy-proven rejections, 
excluding subclinical and borderline rejections.
BK viremia: studies described either any viremia, viremia from a cut-off level onwards 
or BK nephropathy. If various BK outcomes were reported, any BK viremia was scored. 
The outcome BK therefore is heterogeneous, but comparable between patients from 
the same center. This holds true for cytomegalovirus (CMV) viremia as well.
Severe non-viral infection: for this item heterogeneous outcomes were combined: 
sepsis; hospitalization for infection for 7 or more days; bacterial infection; sepsis; 
pneumonia; fungal infection; Pneumocystis jirovecii pneumonia; bacterial infection 
requiring hospitalization. Urinary tract infections were excluded.
Bleeding: this was a combination of postoperative blood transfusion or bleeding leading 
to surgical intervention, whichever was reported in the included studies.
Follow-up: graft survival was analyzed at year one and if available year three. Rejection, 
infection and bleeding were censored at year one if this information was provided. If not, 
these outcomes were reported during total follow-up of the individual studies. Studies 
reported either mean or median follow-up, making it impossible to determine the 
mean follow-up of patients in the meta-analysis. This mean follow-up was established 
by approximation: mean follow-up was determined by multiplying the total number of 
patients in each study by their corresponding (mean or median) follow-up in months, 
divided by the total number of patients in all included studies.
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Risk of bias assessment
The Newcastle-Ottawa scale was adopted to assess the quality of the retrospective 
cohort studies (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). 
Studies were graded according to selection of study groups, comparability of groups 
and ascertainment of exposure and outcomes. A maximum of nine stars represents the 
lowest risk of bias (Supplemental Table 2 Newcastle-Ottawa checklist).
Statistical analysis
The meta-analysis was performed using Review Manager 5.3 (The Nordic Cochrane 
Centre, Copenhagen, Denmark). Baseline characteristics were descriptive for continuous 
variables and reported group means weighed for number of included patients. For 
the meta-analysis the Mantel-Haenszel analysis method was used. We divided 
the included studies into two subgroups in advance, defining studies with (mainly) 
immunoadsorption versus studies with (mainly) plasmapheresis as antibody removal 
technique. This subgroup analysis was planned because the only meta-analysis so far 
about ABO-incompatible kidney transplantation compared these two desensitization 
techniques (17). Lo et al. demonstrated inferior outcomes after plasmapheresis. 
Statistical heterogeneity was formally assessed with I2 (where 0-40% was considered 
low heterogeneity) and visually by judging overlap in confidence intervals. Differences 
between groups were analyzed with relative risk (RR) ratios at fixed time spans. Risk 
ratios were calculated using a fixed-effect model. If heterogeneity was however higher 
than 40%, a random-effect model was used. Forest plots represent studies in order of 
year of publication. P <0.05 was considered statistically significant.
RESULTS
Literature search results
Figure 1 presents the PRISMA flow chart. After removing duplicates a total of 2728 
unique studies were identified. 750 studies were selected for the ABO-incompatible 
research database, of which 36 described center-matched ABO-incompatible cohorts. 
Of these, 9 were excluded because of missing data on patient and graft survival (18), 
bias due to description of the ABO-incompatible cohort by selecting only surviving grafts 
(19), and because of overlap in patients (20-26). Finally, 26 studies were included in the 
meta-analysis. In these 26 articles, a total of 1346 unique ABO-incompatible patients 
were compared to 4943 center-matched controls. The characteristics of the included 
studies are shown in Table 1.
2
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ABOi: ABO-incompatible   ABOc: ABO-compatible   vs: versus
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of 
the systematic literature search. 
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Baseline characteristics of patients included
Follow-up of ABO-incompatible patients was 37 months versus 40 months in controls 
(Table 2, Supplemental Table 4). Recipients of ABO-incompatible kidney allografts were 
slightly older and had younger donors than ABO-compatible controls (recipients 47 vs 
45 years and donors 48 vs 49 years in ABO-incompatible vs ABO-compatible). Since 
the majority of studies lacked standard deviations for these items, no significance level 
could be determined. This holds true for total number of HLA mismatches on A, B and DR 
loci (3.6 vs 3.1). There were no differences in level of PRA, DSA, retransplants and pre-
emptive transplantations between ABO-incompatible and ABO-compatible patients. 
As expected, ABO-incompatible patients more often received unrelated transplants, 
although this characteristic was only reported on in the minority of studies.





























































* p<0.0005 HLA: human leucocyte antigen MM: mismatch PRA: panel-reactive antibody DSA: donor-specific antibody
Risk of bias
The risk of bias was low: the majority of studies (13) had no bias item, ten studies had 
one bias item and three studies had two bias items (Supplemental Table 3). Examples 
of these bias items were the use of different calcineurin inhibitors and a shorter follow-
up of ABO-incompatible patients. Studies were equally divided into consecutive and 
matched control groups. In the majority of studies criteria for matching were scarcely 
explained. Supplemental Table 5 provides detailed matching information.




All 26 studies reported one-year graft survival. No study found significant differences 
between ABO-incompatible and ABO-compatible uncensored graft survival. Combining 
these data revealed inferior graft survival for ABO-incompatible patients (96% vs 98% 
for controls, p=0.002). The relative risk (RR) for one-year graft survival was decreased in 
ABO-incompatible patients (RR 0.97, CI 0.96-0.98, p<0.0001, I2=0%; p=0.47, Figure 2). The 
subgroup analysis dividing plasmapheresis and immunoadsorption revealed the same 
pattern (I2=0%; p=0.66 for subgroup differences). Graft survival remained inferior at three 
years (92% vs 94%, p=0.037, Supplemental Figure 1). However, ABO-incompatible grafts 
surviving after one year had comparable outcomes to ABO-compatible controls three years 
after transplantation: uncensored graft survival between one and three years was 97% for 
both ABO-incompatible and ABO-compatible patients (p=0.70, Supplemental Figure 2).
ABOc: ABO-compatible ABOi: ABO-incompatible 95% CI: 95% confidence interval M-H: Mantel-Haenszel.
Figure 2. Forest plot of comparison: ABO-incompatible kidney transplantation versus center-matched 
ABO-compatible control patients; outcome: One-year uncensored graft survival. Subgroup analysis: plas-
mapheresis versus immunoadsorption.
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One-year patient survival was lower for ABO-incompatible patients (98% vs 99%, 
p=0.03). The relative risk for one-year patient survival in ABO-incompatible patients was 
0.99, CI 0.98-1.00, p=0.009, I2=0%; p=0.66 (Figure 3). Fifteen articles reported on causes 
of death during the follow-up period. In ABO-incompatible patients 49% of reported 
causes of death were of infectious origin, versus only 13% in ABO-compatible patients 
(p=0.02; ABO-incompatible: 18 infection, 1 malignancy, 15 miscellaneous, 3 unknown 
versus ABO-compatible: 6 infection, 5 malignancy, 24 miscellaneous, 3 unknown, 9 
not reported).
ABOc: ABO-compatible   ABOi: ABO-incompatible   95% CI: 95% confidence interval   M-H: Mantel-Haenszel.
Figure 3. Forest plot of comparison: ABO-incompatible kidney transplantation versus center-matched 
ABO-compatible control patients; outcome: One-year patient survival. Subgroup analysis: plasmapheresis 
versus immunoadsorption. 
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ABMR: antibody-mediated rejection ABOc: ABO-compatible   ABOi: ABO-incompatible   95% CI: 95% confidence interval 
M-H: Mantel-Haenszel.
Figure 4. Forest plot of comparison: ABO-incompatible kidney transplantation versus center-matched 
ABO-compatible control patients; outcome: Antibody-mediated rejection. 
Rejection
22 studies reported on rejection. Biopsy-proven acute rejection was more common 
in ABO-incompatible patients (RR 1.39, CI 1.19-1.61, p<0.0001, I2=38%; p=0.05, Table 
3), especially antibody-mediated rejection (RR 3.86, CI 2.05-7.29, p<0.00001, I2=60%; 
p=0.001, random-effect model, Table 3, Figure 4).
Infection
Severe non-viral infection
17 studies reported infectious episodes. Severe non-viral infections occurred more often 
in ABO-incompatible patients (RR 1.44, CI 1.13-1.82, p=0.003, I2=39%, p=0.06 Table 3).
Viral infection
18 studies reported CMV, either viremia or disease. CMV viremia was slightly more common 
in ABO-incompatible patients (RR 1.20, CI 1.04-1.37, p=0.01, I2=17%, p=0.26, Table 3).
BK viremia was more common in ABO-incompatible patients in nine studies, did not 
occur in two studies and was less common in four studies (RR 1.70, CI 1.14-2.56, p=0.01, 
I2=45%, p=0.03, random-effect model, Table 3).
Bleeding
Nine studies included a table with bleeding-related parameters. These outcomes 
occurred almost twice as often in ABO-incompatible versus ABO-compatible 
patients (RR 1.92, CI 1.36-2.72, p=0.0002, I2=10%, p=0.35, Table 3), both with 
immunoadsorption and with plasmapheresis (I2=0%, p=0.84 for subgroup differences, 
Supplemental Figure 3).
2
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1.92 [1.36 – 2.72] < 0.001
CI: confidence interval CMV: cytomegalovirus RR: relative risk
DISCUSSION
ABO-incompatible kidney transplantation, as performed in the last decade, is considered 
safe as compared to ABO-compatible transplantation. The current meta-analysis shows 
that ABO-incompatible kidney transplant recipients have very good outcomes, but 
with a higher risk of losing their allograft within one year after kidney transplantation 
compared to center-matched ABO-compatible controls. In addition, the risks for severe 
infection, viral infection, antibody-mediated rejection and post-operative bleeding were 
all higher in the ABO-incompatible patient group.
Although inferior graft survival in the ABO-incompatible group was a consistent 
finding in the 26 studies included for analysis, it was not significant in any of these 
studies, because of insufficient number of patients per study. However, inferior graft 
survival has been described in some registry studies. United Network for Organ Sharing 
data for instance reveal inferior graft survival within the first year and, similar to the 
results of the meta-analysis, grafts surviving thereafter had comparable outcomes to 
ABO-compatible patients (45). Early graft losses occurred in the direct postoperative 
period (within 14 days) in a relatively large cohort of ABO-incompatible patients 
described by Montgomery et al. (13). A Japanese registry also revealed inferior one-year 
graft survival (46), but both these Japanese and American cohorts contained patients 
treated with splenectomy.
The largest registry study, especially in the modern era without splenectomy, the 
Collaborative Transplant Study (CTS) by Opelz et al. and Morath et al. (10, 11) described 
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1420 ABO-incompatible patients. Their outcomes show similar death-censored graft 
survival rates for ABO-incompatible versus ABO-compatible transplantation. However, 
there was a slightly decreased one-year patient survival in the ABO-incompatible group 
owing to infectious-related deaths. Our data are limited on cause of death but reveal 
the same pattern, with infection as cause of death in half of the ABO-incompatible 
patients versus only 13% of ABO-compatible patients. These findings are in accordance 
with a Korean ABO-incompatible registry reporting inferior patient survival due to 83% 
infection-related deaths compared to only 27% in ABO-compatible controls (12).
These registry studies lack a comparison of baseline characteristics between the 
ABO-incompatible and ABO-compatible cohorts but their outcomes strengthen the 
results of our meta-analysis: ABO-compatible controls in the meta-analysis were 
either matched or consecutive, leading to similar baseline clinical and demographic 
characteristics between the groups. Therefore it seems that the inferior outcomes after 
ABO-incompatible kidney transplantation cannot be contributed to “unchangeable” 
patient characteristics but to the procedure itself.
The explanation for the higher infection-related one-year mortality after ABO-
incompatible kidney transplantation is speculative as data analysis on the single patient 
level was not possible. For example it could not be deciphered if antibody-mediated 
rejection and patient death coincided. Other potential factors that may have resulted 
in a higher risk of severe infection are induction therapy and plasmapheresis. The vast 
majority of patients in the included studies received rituximab induction. Rituximab 
induction on top of a standard immunosuppressive regime is considered relatively safe 
and was not associated with infection in a large randomized trial in kidney transplant 
recipients (47). In the CTS registry, rituximab resulted in better death-censored graft 
survival compared to no induction therapy, arguing against a major effect of rituximab 
on infectious complications (11). The removal of protective immunoglobulins by 
plasmapheresis may contribute to a higher risk for infection. However, there was 
no difference in mortality and infectious complications between patients receiving 
immunoadsorption versus plasmapheresis. This is contrary to a meta-analysis of 4810 
ABO-incompatible patients stratified according to desensitization technique (17): in 
this study by Lo et al., after a mean of 26 months follow-up, overall graft survival was 
significantly worse after plasmapheresis compared to immunoadsorption.
Of note is the doubled risk of bleeding in ABO-incompatible patients, irrespective of 
plasmaphersesis technique used. This is a consistent finding in Dutch immunoadsorption 
patients (48).
This meta-analysis reveals that ABO-incompatible transplantation has very good 
outcomes, albeit inferior than ABO-compatible transplantation: the overall uncensored 
graft loss at one year post-transplantation was 4.2% in the ABO-incompatible and 2.5% 
in the ABO-compatible patient group. These outcomes are favorable compared to 
remaining on dialysis or receiving a deceased donor kidney allograft (49). However, 
it also indicates that the ABO-incompatible procedure with its specific complications 
is associated with a higher one-year graft loss and mortality, although the absolute 
2
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numbers remain low. In this is the strength of this meta-analysis, since the ABO-
incompatible literature lacks randomized controlled trials and guidelines are based 
on cohort studies generally lacking power to detect low-frequency clinically relevant 
differences. Statistical heterogeneity for graft and patient survival was very low in this 
meta-analysis. This information can assist transplant candidates and their doctors in 
balanced clinical decision making. It is also a further incentive to promote the use of 
kidney exchange programs allowing for ABO-compatible matches to be made in case 
of ABO incompatibility.
Publication bias is a limitation of this meta-analysis. The discussions of the included 
studies generally conclude favorable ABO-incompatible outcomes. Less favorable 
ABO-incompatible outcomes might be left unpublished and the true additive risk of 
ABO-incompatibility might be higher. An important consideration is that some patients 
cannot proceed to transplantation despite ABO-incompatible desensitization. Becker et 
al. for example report desensitization failures in 5 out of 39 procedures (28). Since this 
meta-analysis only includes transplanted patients, the true burden of ABO-incompatible 
desensitization is probably higher. Other limitations are the lack of individual patient 
data and the inconclusive reporting of match criteria. Completeness of reporting of 
adverse events and the observation period after transplantation differed between 
studies. Follow-up of ABO-incompatible patients was shorter than controls. This 
however may suggest that the higher incidence of complications observed after ABO-
incompatible kidney transplantation is a conservative estimation. Given the slightly 
inferior results of ABO-incompatible kidney transplantation, it is important to optimize 
the possibilities for compatible transplantation: national or regional kidney exchange 
programs are therefore of proven value and utmost importance to improve outcomes 
after living kidney transplantation (50).
In conclusion, ABO-incompatible kidney transplantation has very good outcomes 
but is associated with a greater risk for graft loss and lower patient survival within the 
first year after transplantation compared to ABO-compatible controls.
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ABO-incompatible kidney transplant outcomes: A meta-analysis. How safe is crossing 
the ABO blood group barrier?
Supplemental Table S1. Search criteria.
Embase.com
(‘blood group ABO incompatibility’/de OR ‘blood group incompatibility’/de OR 
(((abo OR ab0 OR ‘blood group’ OR ‘type A’ OR ‘type A2’ OR ‘type A1’ OR ‘type 
B’ OR ‘type AB’ OR ‘type O’) NEAR/6 (incompatib* OR mismatch* OR barrier* OR 
antibod*))):ab,ti) AND (‘kidney transplantation’/exp OR ‘renal graft dysfunction’/
exp OR ‘kidney donor’/de OR (transplantation/de AND kidney/exp) OR ((kidney* OR 
renal*) NEAR/3 (transplant* OR homotransplant* OR autotransplant* OR graft* OR 
allograft* OR donor* OR donat* OR recipient*)):ab,ti)
Medline 
(OvidSP)
(“Blood Group Incompatibility”/ OR (((abo OR ab0 OR “blood group” OR “type A” OR 
“type A2” OR “type A1” OR “type B” OR “type AB” OR “type O”) ADJ6 (incompatib* 
OR mismatch* OR barrier* OR antibod*))).ab,ti.) AND (“Kidney Transplantation”/ 
OR kidney/tr OR ((kidney* OR renal*) ADJ3 (transplant* OR homotransplant* OR 
autotransplant* OR graft* OR allograft* OR donor* OR donat* OR recipient*)).ab,ti.)
Cochrane
((((abo OR ab0 OR ‘blood group’ OR ‘type A’ OR ‘type A2’ OR ‘type A1’ OR 
‘type B’ OR ‘type AB’ OR ‘type O’) NEAR/6 (incompatib* OR mismatch* OR 
barrier* OR antibod*))):ab,ti) AND (((kidney* OR renal*) NEAR/3 (transplant* OR 




TS=(((((abo OR ab0 OR “blood group” OR “type A” OR “type A2” OR “type A1” OR 
“type B” OR “type AB” OR “type O”) NEAR/6 (incompatib* OR mismatch* OR barrier* 
OR antibod*)))) AND (((kidney* OR renal*) NEAR/3 (transplant* OR homotransplant* 
OR autotransplant* OR graft* OR allograft* OR donor* OR donat* OR recipient*))))
Google 
Scholar
“ABO|ab0 incompatibility|incompatible “kidney|renal 
transplantation|graft|allograft|donor|donors|donation|recipient”
2
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Supplemental Table S2. Newcastle-Ottawa quality assessment scale cohort studies.
A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability.
Selection
1) Representativeness of the exposed cohort
 a) truly representative of the average kidney transplant recipient *
 b) somewhat representative of the average kidney transplant recipient *
 c) selected group
 d) no description of the derivation of the cohort
2) Selection of the control group
 a) drawn from the same community as the exposed cohort *
 b) drawn from a different source
 c) no description of the derivation of the non-exposed cohort
3) Ascertainment of exposure
 a) secure record (eg medical file) *
 b) structured interview *
 c) written self report
 d) no description
4) Demonstration that outcome of interest was not present at start of study
 a) yes *
 b) no
Comparability
1) Comparability of cohorts on the basis of the design or analysis
 a) study controls for baseline immunosuppression (TAC vs CsA vs mTORI)*
 b) study controls contemporaneity *
Outcome
1) Assessment of outcome
 a) independent blind assessment *
 b) record linkage *
 c) self report
 d) no description
2) Was follow-up long enough for outcomes to occur
 a) yes (one year) *
 b) no
3) Adequacy of follow-up of cohorts
 a) complete follow-up of all subjects accounted for *

b) subjects lost to follow-up unlikely to introduce bias: small number lost
> 90% follow-up, or description provided of those lost*
 c) follow-up rate < 90% and no description of those lost
 d) no statement
TAC: tacrolimus   CsA: ciclosporin   mTORI: mammalian target of rapamycin
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Ashimine, 2014 (16) **** - ***
calcineurin inhibitor
contemporaneity
Barnett, 2013 (27) **** * *** calcineurin inhibitor
Becker, 2015 (28) **** * *** calcineurin inhibitor
Bennani, 2016 (29) **** ** ** follow-up
Bentall, 2014 (30) **** ** *** -
Flint, 2011 (31) **** ** *** -
Genberg, 2008 (1) **** ** *** -
Habicht, 2011 (32) **** ** *** -
Hatekeyama, 2014 (6) **** ** *** -
Hwang, 2013 (33) **** ** *** -
Iwai, 2015 (34) **** ** ** follow-up
Jha, 2016 (35) **** * **
calcineurin inhibitor 
follow-up
Kauke, 2016 (36) **** * *** calcineurin inhibitor
Kim, 2017 (37) **** * *** contemporaneity
Kwon, 2016 (38) **** * *** contemporaneity
Lee, 2016 (39) **** ** ** follow-up
Melexopoulou, 2015 (40) **** * *** calcineurin inhibitor
Okumi, 2016 (7) **** ** *** -
Park, 2016 (41) **** ** *** -
Sanches-Escudero, 2016 (42) **** ** *** -
Schachtner, 2015 (4) **** ** *** -
Shin, 2015 (8) **** ** *** -
Subramanian, 2016 (9) **** ** *** -
Van Agteren, 2014 (43) **** ** *** -
Yokoyama, 2016 (44) **** * *** calcineurin inhibitor
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Supplemental Table S4. Follow-up of patients in the included studies and time span of 
reporting on rejection and infectious complications.








































during follow-up during follow-up
Hwang, 2013 (33)
24
(no detailed follow-up 
information)








during follow-up during follow-up
Kauke, 2016 (36)
12









(no detailed follow-up 
information)


















AnneliesdeWeerd_bnw.indd   42 8-2-2021   10:34:20
43
ABOi: a meta-analysis
Supplemental Table S4 (continued). Follow-up of patients in the included studies and time 
span of reporting on rejection and infectious complications.

















during follow-up during follow-up
Subramanian, 2016 (9)
29
(no detailed follow-up 
information)
12 not applicable
Van Agteren, 2014 (43)
ABOi: 38
ABOc: 38
not applicable not applicable
Yokoyama, 2016 (44)
12






during follow-up during follow-up
ABOc: ABO-compatible   ABOi: ABO-incompatible
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Supplemental Table S5. Selection of study cohort and control group.
Study period study group selection of controls




Barnett, 2013 (27) 2005-11 consecutive
Becker, 2015 (28) 2005-13
DSA-positive patients 
excluded
matching 2:1 (ABOc: ABOi):
one transplantation directly before 
and one directly after ABOi procedure
Bennani, 2016 (29) 2011-15
matching: 1:1






















Hatekeyama, 2014 (6) 2006-13 consecutive
Hwang, 2013 (33) 2009-11
matching:
initial immunosuppressive therapy
Iwai, 2015 (34) 2001-14
all recipients aged >60 years 
with a spousal transplant
consecutive
Jha, 2016 (35) 2011-14 consecutive


















Lee, 2016 (39) 2010-14
FACS-positive crossmatch 
excluded
43 ABOc patients were 





Melexopoulou, 2015 (40) 2005-13
matching 1:1:
‘randomly selected on
the basis of similar baseline 
demographic and clinical
characteristics of donors and 
recipients’
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Supplemental Table S5 (continued). Selection of study cohort and control group.
Study period study group selection of controls








Schachtner, 2015 (4) 2005-12
matching: basiliximab induction, 
maintenance immunosuppression, 
availability of virology screening




Subramanian, 2016 (9) 2007-12 matching not described
Van Agteren, 2014 (43) 2006-12
matching 2:1 (ABOc : ABOi): 
age, number of HLA mismatches
Yokoyama, 2016 (44) 2008-13 consecutive




ABOc: ABO-compatible   ABOi: ABO-incompatible   DSA: donor-specific antibodies   FACS: flowcytometry
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ABOc: ABO-compatible ABOi: ABO-incompatible 95% CI: 95% confidence interval M-H: Mantel-Haenszel.
Supplemental Figure S1. Forest plot of comparison: ABO-incompatible kidney transplantation versus 
center-matched ABO-compatible control patients; outcome: Graft survival uncensored year 3.
ABOc: ABO-compatible ABOi: ABO-incompatible 95% CI: 95% confidence interval M-H: Mantel-Haenszel.
Supplemental Figure S2. Forest plot of comparison: ABO-incompatible kidney transplantation versus 
center-matched ABO-compatible control patients; outcome: Graft survival uncensored between year 
one and year three.
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ABOc: ABO-compatible ABOi: ABO-incompatible 95% CI: 95% confidence interval M-H: Mantel-Haenszel.
Supplemental Figure S3. Forest plot of comparison: ABO-incompatible kidney transplantation versus 
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The first fifty ABO blood group incompatible 
kidney transplantations; the Rotterdam 
experience.
Madelon van Agteren, Willem Weimar, Annelies E de Weerd, Peter 
AW te Boekhorst, Jan NM IJzermans, Jacqueline van de Wetering, 
Michiel GH Betjes.
J Transplant. 2014; 913902.




This study describes the single center experience and long-term results of ABOi kidney 
transplantation using a pre-transplantation protocol involving immunoadsorption 
combined with rituximab, intravenous immunoglobulins and triple immune 
suppression.
Fifty patients received an ABOi kidney transplant in the period from 2006 to 2012 
with a follow-up of at least one year. Eleven antibody mediated rejections were noted 
of which 5 were mixed antibody and cellular mediated rejections. Nine cellular mediated 
rejections were recorded. Two grafts were lost due to rejection in the first year. One-
year graft survival of the ABOi grafts was comparable to 100 matched ABO compatible 
renal grafts, 96 % vs. 99%. At 5 year follow-up, the graft survival was 90% in the ABOi 
vs. 97% in the control group.
Post-transplantation immunoadsorption was not an essential part of the protocol 
and no association was found between antibody titers and subsequent graft rejection. 
Steroids could be withdrawn safely 3 months after transplantation. Adverse events 
specifically related to the ABOi protocol were not observed.
The currently used ABOi protocol shows good short- and mid-term results despite 
a high rate of antibody mediated rejections in the first years after the start of the 
program.
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INTRODUCTION
Matching for the antigens of the human ABO blood group system is necessary 
when foreign cells or organs are considered for donation. If not matched properly, 
the circulating anti-A and/or anti-B blood group antibodies of the recipient will bind 
to the antigenic moieties of the cell surface-bound A and B blood group molecules 
within the kidney transplant (1). The antibodies attached will activate the complement 
system leading to local cell damage and eventually cell and organ destruction (2). 
Therefore, ABO-incompatible (ABOi) kidney transplantation carries a high risk for 
acute and irreversible antibody mediated rejection and cannot be performed without 
pretreatment of the recipient (3, 4).
Pretreatment of the recipient is aimed at substantial lowering of the concentration 
of circulation antibodies before transplantation and reducing the subsequent 
production of these antibodies. To this end, a number of protocols have been developed 
that originally included plasmapheresis for antibody removal and splenectomy for 
permanent reduction of antibody production. In most protocols, high dose intravenous 
immunoglobulins were also peri-operatively given as this exerts a pleiotropic immune 
suppressive effect, particularly in the case of antibody mediated immune diseases. 
However, in recent years new protocols have been developed based on the use of the B 
cell depleting antibody Rituximab and the availability of an immunoadsorption column 
that specifically binds anti-A or anti-B antibodies. This column is able to clear efficiently 
these antibodies from the plasma, thereby obviating the need for plasma exchange. 
The Swedish ABOi kidney transplantation protocol was among the first that successfully 
combined these new treatment modalities into a highly effective pretreatment protocol 
(5). Published data have shown remarkably good short- and long-term acceptance and 
functioning of the ABOi transplanted kidneys using this protocol (6, 7).
In our transplantation center in the Netherlands we adopted the Swedish protocol 
and started the ABOi transplantation program in 2006. Over the years we have left 
out parts of this protocol and the use of steroids was stopped after 3 months in the 
post-transplantation period, similar to our standard immune suppressive protocol for 
ABOc patients.
The long-term results of the first 50 ABOi kidney transplants in a period of 5 years 
are now reported in detail and safety and long-term results are in accordance with other 
reports. However, early antibody mediated rejections were observed more frequently 
than previously described although in the majority timely treatment was effective. Post-
operative removal of antibodies and continuation of prednisone beyond three months 
after transplantation did not appear to be essential for the success of the program.
3




Living ABOi kidney donor-recipient combinations were evaluated for the ABOi procedure 
after routine pretransplantion screening. Patients with titers of IgM and IgG antibodies 
against blood group A or B below or equal to 1:128 were considered eligible for ABOi 
kidney transplantation. At first, only O recipients and AB donors were included. The 
remaining ABOi couples participated in the Dutch national kidney exchange program, 
because of their good chance to find suitable donors. The protocol described by Tyden 
et al. (5) was followed with the exception that plasma for immunoadsorption was 
generated from the blood by a plasma separating dialyzer and not by centrifugation. 
The immunoadsorption was performed using a specific adsorption column for anti-A 
or anti-B antibodies (Glycorex Transplantation AB, Lund, Sweden). If needed, the 
routine hemodialysis session was combined with the immunoadsorption procedure. 
Such a simultaneous session was performed without specific problems and with 
similar adequacy as immunoadsorption alone. All patients were given a single dose 
rituximab (375 mg/m2) one month prior to kidney transplantation. Two weeks before 
transplantation, mycophenolic acid (1000 mg bid), tacrolimus twice daily (target through 
level 10-15 μg/L) and prednisone 20 mg once daily were given. The immunoadsorption 
procedure was performed daily before the transplantation. The number of sessions 
was dependent on the height of the titer of anti-donor blood group antibodies 
and the rebound after every session. Therefore, the number of pretransplantation 
immunoadsorptions varied with a median of 4 sessions (range 0 to 7). During the 
procedure 6 liters of plasma were passed over the column and antibody titers were 
assessed before and after the procedure. The kidney transplantation was performed 
the day after the last immunoadsorption but only if the post-adsorption IgM and IgG 
antibody titers were below 1:8. In 4 patients no immunoadsorption was performed as 
the anti-ABO titers were already <1:8. Following the original protocol, we performed 
3 immunoadsorptions at days 1, 4 and 7 post-operatively in the first 25 patients. The 
day before kidney transplantation, after the last immunoadsorption, 0.5 gram/kg IVIG 
was given. In all patients, prednisone was stopped 3 months after transplantation and 
tacrolimus through levels were adjusted to 5-10 μg/L, following our standard post-
transplantation treatment protocol. No T-cell depleting agent was used for induction 
therapy.
The percentage of CMV seropositive patients was 66% and routinely all our 
transplantation patients, except for CMV-/- combinations, received prophylaxis with 
valganciclovir during the first 6 months after kidney transplantation. Routine kidney 
biopsies were performed in the first years of our ABOi kidney transplantation program 
but this policy was abandoned, as it did not contribute to clinical decision-making (see 
results section).
A kidney biopsy by indication was performed if rejection was suspected on the 
grounds of an unexpected halt in improvement or worsening of kidney function. 
Histological confirmation of rejection was obtained by following the Banff criteria 07 
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for acute cellular en antibody mediated rejection (AMR). Acute AMR was treated with 
extra immunoadsorptions, high dose steroids (1000 mg prednisolon/day for 3 days) 
and IVIG (1 gram/kg). In case of unresponsiveness, T-cell depleting therapy was given 
according to our local protocol.
The first 25 patients received post-operative immunoadsorptions per protocol 
and were routinely monitored for isoagglutinin titers after transplantation. As the 
isoagglutinin titers remained low and no rebound occurred, we abandoned the policy 
of routine post-transplantation immunoadsorptions.
For the purpose of comparison, 2 cases of ABO compatible kidney transplantation 
were selected from the same period and matched for age and number of HLA 
mismatches for every case of ABOi kidney transplantation. The post-transplantation 
immunosuppressive medication protocol was similar to the ABOi protocol except for 
induction therapy with basiliximab in all patients from 2007 onwards.
Determination of antibody titers
Patient serum was tested for the presence of IgM and IgG antibodies against the 
ABO-blood group antigens of the donor using the red blood cells (RBC) of the donor. 
Hemagglutination was assessed fully automated using the ORTHO BioVue system 
column agglutination technology. Test RBC, with or without serum, were placed in the 
chamber above the 6-microcolumn cassette preloaded with diluent and/or reagent 
and glass beads. Upon centrifugation, RBC are forced through the bead column where 
agglutinated cells are trapped, while unagglutinated RBC travel to the bottom of the 
column, forming a discrete pellet. The isohemagglutinin titer is determined by the 
highest dilution of patient serum that still results in donor RBC agglutination.
Statistical analysis
The SPSS software version 18.0 was used for all statistical tests. Descriptive statistics 
were used to summarize baseline characteristics. Distribution of data was tested using 
the Kolmogorov-Smirnov test. Continuous variables with a normal distribution are 
presented as means (SD) and compared using parametric t-tests. Skewed distributed 
continuous variables are presented as medians and compared using the non-parametric 
Mann-Whitney test. Categorical variables are presented as numbers and/or percentages. 
For selected comparison between two group proportions, the chi-square test was used. 
Survival percentages were analyzed with the Kaplan-Meier method. A p-value of less 
than 0.05 was considered significant; all probabilities were 2-tailed.
RESULTS
Patients’ characteristics
From the start of the ABOi program in 2006 until March 2012, a total of 50 patients 
received an ABOi kidney transplant from a living donor. Clinical follow-up was at 
3
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least one year with a median follow-up of 38 months. The clinical and demographical 
patient characteristics are shown in Table 1. The majority of ABOi donor-recipient 
combinations were from an A and/or B positive donor to an O positive recipient (Table 
1). This selection is caused by our national living kidney donor exchange program, which 
can accommodate an appropriate ABO compatible match for most cases except the O 
recipients and A and B donors.
Table 1. Clinical and demographic characteristics of patients receiving a blood type ABO-
incompatible (ABOi) kidney transplant and matched ABO-compatible (ABOc) controls.
ABOi ABOc p-value
number of patients 50 100
age recipient (median and range) 54 years (22-75) 55 years (19-77) n.s.*







previous transplantation (%) 18 % 13 % n.s.
previous pregnancy (%) 30 % 34 % n.s.
previous blood transfusion (%) 20 % 24 % n.s.
pre-emptive transplantation 10 (20%) 10 (10%) n.s.
number HLA MM (median) 4 4 n.s.
ABO blood group recipient









% of patients with panel reactive antibodies >4 %** 10% 4% n.s.
*n.s.: not significant (p-value >0.05) **most recent % of panel reactive antibodies positivity obtained before kidney 
transplantation. A PRA of <5% was considered as negative by the reference laboratory (Leiden, the Netherlands).
Kidney allograft survival of ABOi transplantations
The majority of ABOi patients showed an uncomplicated clinical course and graft survival 
censored for death at 1 year, 3 years and 5 years was 96%, 90% and 90% compared to 
respectively 98%, 96% and 96% in the ABOc group (Figure 1). ABOi graft survival was 
slightly worse but not statistically different from the ABO compatible control group (log 
rank analysis p=0.43). Two patients in the ABOi group died during follow-up; one suicide 
and one patient because of abdominal sepsis due to an incarcerated hernia cicatricalis. 
Serum creatinine concentrations at 1 and 3 years follow-up were significantly higher 
(p <0.05) in the ABOi group (median 137 umol/L and 154 umol/L) compared to the 
ABOc group (median 114 umol/L and 123 umol/L). This difference in graft function was 
largely attributable to the decreased graft function in ABOi patients after their AMR 
had resolved. The median serum creatinine concentration in the ABOi patient group 
without AMR was 135 umol/L at 1 year and 124 umol/L at 3 years follow-up. For ABOi 
patients with early AMR these values were 172 umol/L and 172 umol/L, respectively. 
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Two patients had an exceptionally poor renal function at 3 months post-transplantation. 
One case was caused by a surgical problem leading to severe problems with renal 
blood supply and subsequent partial renal infarction and the other case was due to 
an AMR resistant to treatment. Of note is one patient that presented 3 months post-
transplantation with an urosepsis with Serratia species and a very severe acute AMR 
necessitating transplantectomy. Anti-A titers had sharply risen (IgM >5000 and IgG 
512).
Kidney allograft rejection of ABOi transplantations
In eleven patients acute AMR was observed, all within the first week after transplantation 
except for the case of late acute AMR described above. Donor specific antibodies against 
HLA were only found in 2 patients, both having anti-HLA-DQ7 antibodies with a MFI of 
20.000 in the single antigen beads Luminex assay. The C4d staining was positive in 8 
biopsies, weak to focally positive in 2 and negative in 1 kidney biopsy. Five of these early 
rejections were categorized as AMR at the time of biopsy and responded to treatment 
with IVIG and steroids. In 5 cases the renal biopsy showed a mixed type rejection with 
evidence for the co-existence of both cellular and AMR. T-cell depleting therapy was 
used in case of an inadequate response to IVIG and steroids. In one of these patients 
graft loss occurred 3 months after transplantation because of treatment resistant AMR. 
One patient had an acute cellular rejection at 7 months when his tacrolimus through 
level was inadvertently low.
Routine allograft kidney biopsies at day 7 after kidney transplantation showed C4d 
positive staining in 8 out of 19 (42%) patients but without other positive criteria to 
support the diagnosis of AMR.
We could not find any significant relation between antibody titers post-operatively 
and subsequent AMR, as all titers remained low after transplantation (<1:8, data 
not shown). Because of this observation, we stopped the post-transplantation 
Figure 1. Renal allograft survival 
censored for death in the blood 
group ABO incompatible (n=50) 
and matched ABO compatible 
(n=100) transplantations.  
Numbers of patients in study at 
every year after transplantation 
are shown below the x-axis.
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immunoadsorptions after the first 25 patients. This change in protocol did not alter the 
frequency of AMR and in fact most AMR episodes were observed in the patients that 
received post-transplantation immunoadsorptions (9 out of 11 patients with AMR). In 
the group of ABOi patients with an early AMR episode only one patient was diagnosed 
with transplant glomerulopathy seven years after transplantation.
Adverse events
All adverse events, possibly related to a change in immune suppression, notably the 
use of rituximab and IVIG, were recorded. The post-transplantation viral infections in 
the ABOi group were caused by cytomegalovirus (n=2), BK virus (n=3) and herpes zoster 
virus (n=3). In addition, 1 case of Pneumocystis carinii pneumonia was recorded. The 
frequency of these infections is in the range of our ABO compatible program and cannot 
be specifically related to the use of rituximab or IVIG.
DISCUSSION
Newly developed desensitization protocols have greatly facilitated the development of 
ABOi kidney transplantation programs in many countries. Similar to other groups, we 
have successfully applied the Swedish desensitization protocol for more than 5 years 
and did not observe any significant side effects. By combining the immunoadsorption 
procedure with hemodialysis it was also possible to reduce the total number of 
procedures. This is not only time-effective but also less burdensome for dialysis 
patients.
In accordance with a number of other studies (8-11), the graft survival of ABOi kidney 
transplants was not significantly different from matched ABOc kidney transplants. 
However, it should be noted that the median serum creatinine concentration in the 
ABOi group was higher at follow-up compared to the ABOc group. This was due to 
the subgroup of ABOi patients who experienced an AMR. Although the rejection 
episodes could be treated effectively in most of these patients, the graft function was 
permanently negatively affected. However, progressive loss of graft function because 
of ongoing AMR was not observed and overall 5 years graft survival was therefore not 
significantly lowered compared to the ABOc group. However, the median follow-up of 
3 years is relatively short and close monitoring of the ABOi graft results is mandatory. 
Most cases of AMR occurred within the first 25 patients (9 out of 11 patients with 
AMR) included in the program and were related to ABO incompatibility, as we could 
detect DSA only in 2 cases. In spite of a thorough analysis of our procedure we cannot 
explain the high frequency of AMR at the start of our ABOi program with a subsequent 
decrease. The frequency of AMR in our study is in contrast to publications by other 
groups using an identical protocol (8, 9, 12) but a similar or higher rate of rejection 
has been described by others using different pretransplantation desensitization 
procedures (12-14). This highly variable incidence of AMR between the published case 
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series is difficult to explain. Although different definitions of acute rejection may play 
a role, our definition of a rise in serum creatinine concentration combined with biopsy 
proven AMR did not leave any uncertainty about the diagnosis. Others have found an 
increased frequency of AMR in blood group O recipients (15), which may have negatively 
influenced our results, as the majority of patients in our study carried the blood group 
O serotype. However, Tyden et al. had a similar high percentage of these patients in 
his ABOi program but still had a remarkably low incidence of AMR (7). Therefore, the 
relevance of the O blood group in the recipient remains an open question.
In agreement with the experience of others (16, 17), we used an upper limit for 
anti-ABO IgG antibody titers of 1:256 to allow patients to enter our program. Notably, 
the determination of anti-donor blood type antibody titers is susceptible to subjective 
interpretation of the semi-quantitative test result and the same serum sample may 
give very different results when independently tested in different laboratories (18). This 
large variation in determination of titers precludes any sound comparison between the 
results from different centers and may partly explain the differences in the incidence 
of AMR. In our protocol we excluded patients with high anti-ABO blood group titers, 
as it was very difficult to reach a titer of <1:8 in these cases. However, it is not known 
what constitutes a safe threshold for the pretransplant antibody titer. Again, the lack 
of a uniform and reliable test for measurement of antibody titers limits analysis of the 
combined published data.
We did not observe a relation between post-transplantation anti-A/B titers and 
rejection, and all post-transplantation titers remained low. Therefore, we removed 
the post-transplantation immunoadsorptions from the protocol. As stated before, 
the frequency of AMR actually was lower in the 25 patients who did not receive the 
post-operative immunoadsorptions. Other groups have also reported on the results 
of ABO-incompatible transplantation without post-transplantation plasmapheresis or 
immunoadsorption, confirming that such a strategy can indeed be followed without a 
significant increase in the incidence of AMR (11, 13, 14, 19).
The combined elements of the current ABOi protocol have been chosen on a 
rationale based on the proposed mechanism of action of each drug. For instance, 
pretreatment with rituximab depletes the circulating B-cell population. This may be 
important in the prevention of increased anti-A and anti-B antibody synthesis after ABOi 
kidney transplantation as ritixumab treatment diminishes de novo humoral immune 
responses. However, a recent report showed that a rituximab-free ABOi protocol yields 
similar excellent short- and long-term results after kidney transplantation (20). This is 
of considerable interest as rituximab treatment is not only costly but also has been 
associated with increased frequencies of viral infections including BK and polyoma 
viral infections (8, 21, 22).
Given these results, it seems that a simplified protocol with immunoadsorption and 
immune suppressive drugs in the pretransplantation period is equally effective. The 
need for IVIG in the ABOi protocol remains to be established as this is not a standard 
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procedure in some other ABO-incompatible kidney transplantation protocols (8, 14, 
19, 23).
After transplantation we routinely stopped prednisone and continued with tacrolimus 
and MMF. Others found that this policy may lead to an increase in the incidence of acute 
rejection and is associated with a decreased graft survival (24). However, prednisone 
could be safely stopped at 3 months after ABOi kidney transplantation in our group of 
patients.
In conclusion, the use of the “Swedish protocol” with immunoadsorption, IVIG 
and rituximab added to a standard triple immune suppressive regimen, has been used 
successfully for more than 5 years in our transplantation center despite an initial high 
frequency of AMR. It allows for ABOi kidney transplantation with good long-term graft 
survival comparable to ABO compatible kidney transplantation. Important questions, 
such as the upper level of anti-A and anti-B titers that can be accepted before kidney 
transplantation and the optimal preconditioning treatment, remain to be answered. 
The ABOi treatment protocol is of value for those patients that cannot be matched to a 
donor kidney because of blood group incompatibility. Although our center is involved in 
an effective national donor kidney exchange program, the O-positive recipients benefit 
in particular from the ABOi protocol as they have the lowest chance of success in the 
kidney exchange program (25, 26).
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Pre-transplant removal of anti-blood group ABO antibodies is the cornerstone of 
all current ABO-incompatible (ABOi) transplantation programs. In our protocol, 
plasmapheresis (PP) is performed with a plasmafilter followed by immunoadsorption (IA) 
of anti-ABO antibodies. The bleeding complications of this technique are not known.
Methods
We analysed the data of all 65 consecutive ABOi kidney transplantations between March 
2006 and October 2013 and compared these with matched 130 ABO-compatible (ABOc) 
kidney transplantations. Cases differed from controls in the preoperative regimen 
which included IA-PP and rituximab, tacrolimus, mycophenolate mofetil, prednisone 
and immunoglobulines. Data on platelet count, blood loss and red blood cell (EC) 
transfusions during 48 hours postoperatively were collected.
Results
ABOi patients received EC transfusions more frequently than controls (29% vs. 12%, 
p=0.005). Intra-operative blood loss was higher (544 vs. 355 ml, p <0.005) and they 
experienced more major bleeding (≥3 EC within 24 hours, 15% vs. 2%, p <0.0005). 
Platelet count decreased by 28% after the pre-operative IA-PP. In a multivariate model, 
only the number of preoperative IA-PPs was associated with the number of ECs given 
(OR per IA-PP 1.9, p <0.05).
Conclusion
ABOi kidney transplant patients have a high postoperative bleeding risk, correlating 
with the number of preoperative IA-PP sessions performed.
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INTRODUCTION
The cornerstone of ABO incompatible (ABOi) and HLA antibody desensitization 
protocols is reduction of pre-existing concentrations of antibodies against ABO blood 
group or HLA antigens within the graft recipient prior to transplantation. In particular, 
ABO-incompatible kidney transplantation is now accepted as a suitable alternative 
transplantation program with excellent outcomes for patient and graft survival. This 
has resulted in increasing numbers of patients receiving an ABOi kidney graft worldwide 
and a better use of the potential of living kidney donors (1-4). Plasmapheresis (PP) is 
an essential procedure within all current desensitization protocols and may consist of 
plasma separation by either a centrifugation technique or by plasmafiltration using a 
large pore hemofilter. During PP the plasma is exchanged for either fresh frozen plasma 
(FFP) or a human albumin solution. In the case of ABO desensitization, the need for 
plasma exchange can be circumvented by the use of immunoadsorption (IA). In this 
particular procedure, the separated plasma is led over an anti-ABO adsorbing column 
before returning to the circulation of the patient. In patients undergoing PP an increased 
risk for hemorrhage has been reported, which can in part be attributed to the removal 
of coagulation factors when plasma is exchanged for albumin solution instead of FFP. In 
addition, the anticoagulants used during PP treatment can cause bleeding complications 
and PP with the centrifugation technique leads to substantial loss of platelets of up to 
50% (5). In PP using the filtration technique an occasional case of platelet depletion was 
described (6), but any association with bleeding tendency has not been reported. Also in 
ABOi kidney transplantation there are indications that the desensitization procedure may 
be associated with a higher incidence of bleeding complications postoperatively (7-9). 
However, there has not been a systematic analysis of bleeding complications associated 
with the ABOi desensitization procedure in a large group of patients compared to ABO-
compatible (ABOc) controls. In our protocol, PP is performed with a plasmafilter followed 
by IA of anti-ABO antibodies using the Glycorex device. To study the possible bleeding 
complications in more detail, we analyzed intra-operative blood loss and the need for red 
blood cell (EC) transfusions in 65 consecutive ABOi kidney transplant patients, compared 
this to 130 matched ABOc controls and studied the causative mechanisms.
MATERIAL AND METHODS
Patients
We analyzed all consecutive patients of a blood group ABOi kidney transplant between 
March 2006 and October 2013 in the Erasmus Medical Center in Rotterdam, the 
Netherlands (n=65). Controls were patients of an ABOc kidney transplant matched for 
age of donor and recipient in this period (n=130). Cases differed from controls in the 
preoperative regimen as has been described in detail before (10). In short, the regimen 
included rituximab 375 mg/m2 4 weeks before transplantation; tacrolimus 0.1 mg/kg 
4
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BID, mycophenolate mofetil 1000 mg BID; prednisone 20 mg once daily starting two 
weeks before transplantation and immunoglobulines 0.5 g/kg one day preoperatively. 
Furthermore, PP was performed pre-operatively in all but three ABOi patients. PP 
was performed with a plasmaFlux PSu filter (Fresenius Medical Care, Bad Homburg, 
Germany) followed by adsorption of anti-ABO antibodies with the Glycosorb® device, 
coated with synthetically derived blood group A or blood group B antigen (Glycorex 
Transplantation, Lund, Sweden). In 4 hours 1.5 L plasma/hour was led over the column, 
using unfractionated heparin infusion 1000 U/hour to prevent clotting. The first 30 
patients additionally received also postoperative IA as per protocol, performed on days 
3, 6 and 9 (or days 2, 5 and 8 depending on the day of surgery). ABOi and ABOc patients 
received the same immunosuppressive regimen after transplantation: tacrolimus 0.1 
mg/kg BID, mycophenolate mofetil 1000 mg BID, prednisone 50 mg BID for three days 
and 20 mg once daily thereafter. All kidney transplant patients in our center receive 
unfractionated heparin 12.000 IU/24hours from 4 hours after renal artery anastomosis 
until postoperative day 5. During implantation, the graft is flushed with heparin.
Data collection
The following data were collected from the medical files: sex and age of donor and 
recipient, ABO blood group, blood urea nitrogen (BUN), dialysis dependency prior to 
transplantation, platelet count before IA-PP, preoperatively and during two weeks 
postoperatively; coagulation tests, including the activated partial thromboplastin time 
(aPTT) and prothrombin time-based International Normalized Ratio (PT-INR); transfusion 
with EC within 48 hours after surgery and during two postoperative weeks. Major 
bleeding was defined as ≥3 EC within 24 hours. Intra-operative blood loss documented 
in the anesthesia files was also recorded.
Statistics
For analysis the data obtained within the total ABOi and ABOc patient groups were 
compared for the first 48 hours after surgery. After this period, the ABOi group was 
divided into two groups of patients, one that had received postoperative IA-PP and 
one group that had not. Data were analyzed using GraphPad Prism version 6.0. Mann-
Whitney U test, Wilcoxon signed rank test, paired t-test and unpaired t-test were used 
to determine differences between groups. Fisher’s exact test was performed on discrete 
variables. Multivariate binary regression analysis was performed on variables known for 
influencing the risk of bleeding, e.g. blood group O (11, 12). For this analysis IBM SPSS 
Statistics 21 was used. The statistical significance level was determined as p ≤0.05.
RESULTS
Baseline characteristics
Age and sex of donors and patients did not differ between groups. Patients did not differ 
in age (54 vs. 53 years in controls, p >0.1) with the majority of patients being male (68% 
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vs. 67% in controls). More ABOi patients were on dialysis than controls (72 vs. 55%, 
p <0.05) and their BUN was significantly higher than that of ABOc patients, 25 vs. 21 
µmol/L (Table 1). As expected, blood group O was overrepresented in the ABOi program 
(65%), since their anti-ABO antibodies against all non-type O donors limit their donor 
pool. In ABOc controls the reverse phenomenon was present: 38% of patients were 
blood group O, which is less than the reported prevalence (47%) of blood group O in 
blood donors in the Netherlands. A median of 4 IA-PPs was performed pre-operatively, 
with a range of 0 to 10 sessions depending on the original anti-ABO titer and its decline 
during treatment with IA-PPs (Table 1).
Immunoadsorption plasmapheresis substantially lowers platelet count but does 
not result in changes of coagulation tests
The platelet count before the start of the IA-PP was 233 x109/L on average, comparable 
to a mean of 230 x109/L in ABOc controls one day preoperatively (p >0.1). However, 
after the preoperative IA-PPs platelet count decreased with 28%, leading to 169 x109/L 
platelets on average one day preoperatively in ABOi patients (p <0.0001, Figure 1). 
This decline in platelet count led to a preoperative platelet count of <100 x109/L in 14 
patients (22% of ABOi patients), which was different from the control group, where 
only one patient (1%) had a platelet count <100 x109/L (p <0.0001). One week after 
transplantation the platelet count was comparable to preoperative levels (mean 178 
x109/L day 7) and returned to pre-IA-PP levels after two weeks in the patients receiving 
only preoperative IA-PP (n=35, mean 223 x109/L day 14).
Table 1. Baseline characteristics of ABO-incompatible and ABO-compatible kidney transplant 
patients.
ABO-incompatible ABO-compatible P
number of patients 65 130 -
age recipient (mean, SEMa) 53.6 (1.7) 53.5 (1.1) n.s.
male sex recipient (number, %) 44 (68) 87 (67) n.s.
BUNb day -1 (mmol/l, mean, SDc) 25 ± 9 21 ± 7 <0.005
dialysis dependency (number, %) 47 (72) 71 (55) <0.05













number of preoperative 
plasmapheresis (median, IQRd)
4 (2) - -
number of postoperative 
plasmapheresis n=30 (median, IQR)
3 (0.25) - -
aPTT (median, IQR) 30 (9.5) 28 (6) n.s.
PT-INR (median, IQR) 1.0 (0.1) 1.0 (0.1) n.s.
 a SEM: standard error of the mean b BUN: blood urea nitrogen c SD: standard deviation d IQR: interquartile range
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The first 30 patients received additional postoperative IA-PP and their platelet count 
remained non-significantly lower within the first week compared to the group with only 
preoperative IA-PP (n=21), but their platelet count was restored to significantly higher 
levels two weeks after transplantation (postoperative IA-PP 291 vs only preoperative 
IA-PP 223 x109/L; p <0.05). The platelet count on day 14 in the group of patients with 
postoperative IA-PP exceeded even the numbers recorded before the desensitization 
procedure started (291 vs. 235 x109/L; p <0.05). Platelet count in the total ABOi group 
remained significantly lower than in ABOc controls from the day prior to transplantation 
to day 10 (all p <0.0005).
Both the aPTT and the PT-INR did not differ between groups (aPTT median 30 sec. 
vs. 28 sec. in controls, p >0.1, laboratory normal range 22-32 seconds; PT-INR median 
1.0 IU both groups, p >0.1, Table 1).
Figure 1. Platelet count in ABO-incompatible patients and their ABO-compatible controls. Platelet count 
before start of the plasmapheresis (PP) (mean 233 x109/L) was comparable to controls (230 x109/L) one day 
preoperatively (p >0.1). Platelet count fell by 28% one day pre-operatively in ABO-incompatible patients 
(169 x109/L, p <0.0001). Platelets in ABO-incompatible patients remained lower up to day 10 compared 
to controls (all p ≤0.001). In the group of ABOi patients with postoperative PP (first 30 patients) plate-
let count was higher after two weeks than without postoperative PP (292 vs. 223 x109/L; p=0.02). Plate-
let count after postoperative PP was even higher at day 14 than before PP (292 vs. 235 x109/L; p=0.02). 
ABOi post-op IA: ABO-incompat-
ible kidney transplant patients 
with pre- and post-operative 
plasmapheresis. 
ABOi pre-op IA: ABO-incompat-
ible kidney transplant patients 
with only pre-operative plas-
mapheresis.   
ABOc controls: ABO-compati-
ble kidney transplant patients 
matched for age of donor and 
recipient, and for period.
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The number of preoperative IA-PPs is strongly associated with the need for red 
blood cell transfusion 48 hours postoperatively
ABOi patients needed EC transfusion more frequently than ABOc controls within 48 
hours postoperatively: 29% of ABOi patients received EC transfusion vs. 12% of controls 
(p <0.005, Figure 2A). In the group of patients that received EC transfusion, more ECs per 
patient were given in the ABOi patients than in controls (median 2 EC vs. 1 EC, p <0.001, 
Figure 2B). The following variables were tested for correlation with the dichotomous 
dependent EC transfusion within 48 hours postoperatively: sex of recipient, age of 
recipient, BUN, dialysis requirement prior to transplantation, platelet count before 
IA-PP, platelet count one day preoperatively both linear and dichotomous <100 x109/L, 
delta platelet count (decrease from IA-PP to one day preoperatively), aPTT, PT-INR, ABO 
blood group, the number of preoperative IA-PPs and intra-operative blood loss. Only 
the number of preoperative IA-PPs and blood group O correlated with the need for EC 
transfusion (univariate analysis: OR 1.9, OR 7.1, all p <0.05). In multivariate regression 
analysis only preoperative IA-PP predicted postoperative EC transfusion within 48 hours: 
the risk of transfusion increased independently with every preoperative IA-PP session 
(OR 1.9, p <0.05, Table 2). Only two of the 18 patients with less than 4 preoperative 
IA-PPs received EC transfusion within the first 48 hours, while 16 of the 44 patients 
with 4 or more IA-PPs received EC transfusion (p <0.05), irrespective of platelet count 
(platelet >100 and PP ≥4: 38% vs. platelet <100 and PP ≥ 4: 40% of patients receiving 
EC in this time period, p >0.9, Figure 3A). The number of preoperative IA-PP sessions 
did influence preoperative platelet count: the 21 patients with less than 4 preoperative 
IA-PPs had a higher platelet count than the 44 patients with 4 or more IA-PP sessions 
(mean 209 x109/L vs. 143 x109/L, p=0.001, Figure 3B).
ABOi blood group O patients received EC transfusion more frequently than non-
group O patients during 48 hours postoperatively (40% vs. 9%, p=0.008). Blood group 
O patients underwent more preoperative IA-PP sessions (median 5 vs. 2, p <0.0001). 
The strong association between blood group O and EC transfusion disappeared after 
correction in multivariate analysis for the number of preoperative IA-PPs.
Major bleeding is more frequent in the ABOi patient group, especially in women
Ten ABOi patients experienced major bleeding within 48 hours postoperatively 
compared to only one ABOc patient (15% vs. 1%, p <0.0001, Figure 2C). Three of 
these ABOi patients underwent relaparotomy, in four patients the anesthesia report 
described massive blood loss and difficult hemostasis with intra-operative blood loss 
ranging from 1200 to 2800 ml. One patient had hypotension and acute kidney injury 
for which hemofiltration was initiated. In the other two patients the major bleeding 
was contributed to “oozing”. Women were overrepresented in major bleeding: 70% 
of major bleeders were female, while only 35% of ABOi patients were female (Fisher’s 
exact test p=0.02).
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ABOi: ABO-incompatible kidney transplant patients    EC transfusion: red blood cell transfusion   
ABOc controls: ABO-compatible kidney transplant patients matched for age of donor and recipient, and for period.
Figure 2. ABO-incompatible patients received red blood cell transfusions more frequently than controls. 
ABO-incompatible patients received blood transfusions more frequently than ABO-compatible controls 
(29% vs. 12%, p=0.005) during 48 hours postoperatively (A). In this time period, more red blood cell (EC) 
transfusions were given in the ABO-incompatible patients needing transfusion than in controls (median 
2 EC vs. 1 EC, p <0.001) (B). ABO-incompatible patients experienced more major bleeding (3 or more EC 
within 24 hours) in 48 hours postoperatively than ABO-compatible controls (15% vs. 1%, p <0.0001) (C). 
ABO-incompatible patients received blood transfusion more frequently from 48 hours after transplantation 
up to day 14 than ABO-compatible controls (40% vs. 15%, p=0.0001) (D). 
Blood transfusion within two weeks postoperatively
A substantial part of ABOi patients needed EC transfusion after the direct postoperative 
period, from 48 hours up to day 14: 40% of ABOi patients received EC transfusion vs. 
15% of controls in this period (Figure 2D, p=0.0001).
Intra-operative blood loss
Of 5 ABOi and 9 ABOc patients data on intra-operative blood loss were missing, all 
in patients without EC transfusion the day of surgery. ABOi patients lost more blood 
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Table 2. Multivariate analysis of need for red blood cell transfusion 48 hours postoperatively.
OR 95% CI P
male sex recipient 0.46 0.10-2.11 n.s.
number of preoperative PP 1.91 1.16-3.16 0.01
platelet count 1 day pre-
operatively
1.01 1.00-1.02 n.s.
blood loss surgery 1.00 1.00-1.00 n.s.
blood group O 3.37 0.36-31.41 n.s.
OR: odds ratio CI: confidence interval PP: plasmapheresis
Hemoglobin level
We studied whether the decision for blood transfusion was made at comparable 
hemoglobin levels. The hemoglobin level in patients receiving EC transfusion 
within 48 hours did not differ between ABOi and ABOc controls: the median hemo- 
globin level the day of EC transfusion was 4.6 vs. 4.8 mmol/L, p >0.1. Hemoglobin 
levels did not differ between ABOi patients before start of IA-PP and ABOc controls 
one day preoperatively (7.3 +/- 0.14 vs. 7.5 +/- 0.08 mmol/L respectively, p >0.1). After 
preoperative IA-PP however, the average hemoglobin level was lower compared to 
ABOc controls one day preoperatively (6.8 +/- 0.15 vs. 7.5 +/- 0.08 mmol/L, p <0.0001). 
The average decrease in hemoglobin concentration from the day before surgery till 
day +2 postoperatively was comparable between ABOi patients and controls (-0.7 vs. 
-0.9 mmol/L, p >0.05), but the former received significantly more EC transfusions. This 
finding is in line with the observation that ABOi patients in general have a higher intra-
operative blood loss and have more major bleedings postoperatively.
 
Figure 3. Plasmapheresis correlates with red blood cell transfusion and with platelet count. Only two of the 
18 patients with <4 plasmapheresis sessions (PP) received red blood cell (EC) transfusion within 48 hours post-
operatively, while in the 44 patients with ≥4 PPs 16 of them received EC transfusion, irrespective of platelet 
count. Platelet >100 and PP ≥4: 38% vs. platelet <100 and PP ≥4: 40% of patients receiving EC in this time period, 
p >0.9 (A). The number of preoperative PPs did influence preoperative platelet count: 21 patients with PP 
<4 had an average platelet count of 209 x109/L vs. 143 x109/L in patients with ≥4 IA, p=0.001 (B).  
Pl: platelet count IA: immunoadsorption
A. B.
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Figure 4. Intra-operative blood loss. ABO-incompatible patients lost more blood intra-operatively than 
ABO-compatible control patients (536 +/- 66 vs. 364 +/- 34 ml, mean and SEM, p <0.005).
Figure 5. Hemoglobin level. Hemoglobin levels were comparable between ABO-compatible patients 1 
day pre-operatively and ABO-incompatible patients before immunoadsorption [7.54 (0.08) vs. 7.34 (0.14), 
P = 0.12], but decreased after pre-operative immunoadsorption [6.79 (0.15), p < 0.0001]. 
DISCUSSION
ABOi kidney transplant patients needed more blood transfusions than their ABOc 
controls. In this cohort of 65 ABOi patients and 130 ABOc controls, ABOi patients had 
more blood intra-operative blood loss, received EC transfusions more than twice as 
frequently as their controls in the first 48 hours postoperatively, and significantly more 
major bleeding was noted.
ABOi: ABO-incompatible kidney transplant 
patients.     
ABOc controls: ABO-compatible kidney trans-
plant patients matched for age of donor and 
recipient, and for period.
ABOi: ABO-incompatible kidney transplant 
patients     
Hb: hemoglobin   
IA: immunoadsorption  
ABOc: ABO-compatible kidney transplant pa-
tients matched for age of donor and recipient, 
and for period.
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The number of IA-PPs appeared to be strongly associated with the need for EC 
transfusion. It has been known that PP via the centrifugation technique leads to 
thrombocytopenia but little is known about thrombocytopenia as a result of PP using a 
plasma filter. In this study, we show that IA by plasma filtration also leads to a remarkable 
decrease in platelet count. However, despite the marked decrease in platelet count in 
our ABOi cohort, the platelet count did not correlate with EC transfusion in uni- and 
multivariate regression analysis. Only the number of preoperative IA-PPs predicted 
postoperative EC transfusion, irrespective of the platelet count. For instance, the higher 
transfusion rate in patients receiving 4 or more IA-PPs was not influenced by platelet 
count. In other words, although frequent IA-PP decreases platelet count, the blood 
transfusion rate is largely independent of the platelet count. The singular association 
between IA-PPs and EC transfusion was further strengthened by our analysis of the 
postoperative period beyond 48 hours. Again in the subgroup of patients receiving 
postoperative IA-PP, we noticed an increased need for blood transfusion as compared 
to the other ABOi patients, while their platelet count was not significantly lower within 
this period.
Our findings are supported by anecdotal data in the literature on a higher bleeding 
tendency in ABOi kidney transplant patients treated with PP, performed with and 
without IA (7-9, 13). The correlation between number of PPs and risk of bleeding can 
be extrapolated from two other studies. ABOi pediatric kidney transplant patients had 
more bleeding complications when more PP sessions were applied (14). Higher anti-
ABO tites necessitating an intensified PP regimen led to more bleeding complications 
compared to low anti-ABO titers in a cohort of 14 Korean ABOi patients (15).
Frequent contact with the plasma filter membrane thus seems to cause a 
bleeding tendency, which may be explained by coagulation abnormalities or platelet 
dysfunction rather than thrombocytopenia. The plasma dialyzer membrane used in 
our ABOi patients is a full barrier for platelets. However, platelet count and function 
are influenced during a hemodialysis session using dialyzers made from similar types 
of synthetic membranes as during PP (16). Daugirdas and Bernardo review this topic 
extensively, including studies on polysulfone membranes and its inhibitory effect on 
platelet count and function (16–18). Platelet count falls approximately 10% during 
the first 30 minutes of dialysis and typically returns to predialysis values thereafter. 
Both the formation of platelet aggregates and the activation of platelets can lead to 
this decrease in platelet count (19). The type of membrane (synthetic vs. cellulose), as 
well as the sterilization method, influence these phenomena (20). The increased blood 
shear stress or the formation of microbubbles might play a role in platelet activation 
(21). Activated platelets have a shortened life-span and prolonged bleeding times can 
be measured directly after hemodialysis (22, 23). Therefore, thrombocytopenia and 
platelet dysfunction may follow repeated PP as a consequence of the procedure and 
materials used, similar to hemodialysis.
Besides platelet dysfunction induced by the polysulfone membrane, coagulation 
abnormalities could be an alternative hypothetical explanation for the higher 
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transfusion need. The normal PT-INR and aPTT argue against this possibility. This is 
further supported by a report on 14 ABOi German patients in whom D-dimer, fibrinogen, 
plasminogen, thromboelastography and antithrombine-III were found to be similar 
before and after PP with IA (8).
Notably, the hemoglobin level in ABOi patients after the preoperative IA-PP sessions 
was lower than in ABOc controls before surgery while a similar transfusion policy 
was used for both groups. This raised the possibility that the EC transfusion rate was 
increased in the ABOi group postoperatively solely because of a lower hemoglobin level 
before surgery. However, the higher intra-operative blood loss and the higher rate of 
major bleeding argue against the lower hemoglobin level pre-operatively as a singular 
explanation for the higher transfusion rate.
Two remarkable findings need to be discussed. Blood group O patients needed 
EC more frequently during 48 hours postoperatively. The association between blood 
group O and EC transfusion could be explained by a higher number of IA-PPs performed 
in patients with blood group O, as a consequence of higher anti-ABO titers in blood 
group O patients (24). Another explanation for the higher transfusion rate might be 
a higher bleeding tendency in blood group O subjects per se. Blood group O is also 
overrepresented in for example women with heavy menstrual bleeding (11) and children 
with post-tonsillectomy hemorrhage (12). The reciprocal also holds true, with a higher 
incidence of thrombosis in non-group O individuals (25). This may be related to the 
25% lower levels of von Willebrand Factor in individuals with blood group O vs. non-O 
(26). Another outcome was the higher risk of major bleeding in women. Studies in 
anticoagulation therapy and management of cardiovascular disease also reveal a higher 
risk of bleeding among women (27). The reason for this bleeding tendency in women 
is not clear.
Our results reveal a higher transfusion rate and bleeding tendency in patients 
undergoing IA-PP. We hypothesize that the causative mechanism is platelet dysfunction 
induced by contact with the plasma filter membrane, combined with blood loss caused 
by the filtration technique. We have not excluded so far the possibility that the higher 
blood transfusion rate was caused by the adsorption column and not the plasma filter 
membrane alone. Fibrinogen levels can indeed be significantly reduced after IA (28). 
More bleeding compared to controls, however, was also observed in ABOi patients 
receiving PP without IA (7, 15). Also the normal coagulation times in our ABOi cohort 
argue strongly against loss of coagulation factors by adhesion to the column, as 
hypofibrinogenemia would prolong coagulation tests, which require the production of 
a fibrinogen clot as an end point, like aPTT and PT-INR.
In conclusion, immunoadsorption plasmapheresis prior to ABOi kidney 
transplantation exposes patients to a significantly higher bleeding risk than ABOc 
controls. Blood transfusion leads to HLA sensitization, especially in patients with 
baseline panel reactive antibodies (29, 30) such as ABOi kidney transplant patients (2, 
7). Therefore, further investigations are warranted to clarify the precise mechanisms 
and to implement anticoagulation protocols for this specific patient category.
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Post-transplantation immunoadsorption can be 
withheld in ABO-incompatible kidney transplant 
recipients.
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After ABO-incompatible kidney transplantation, postoperative plasma exchange (PE) 
or immunoadsorption (IA) is performed per protocol or depending on postoperative 
A/B-titers to prevent acute rejection. However, the need for postoperative PE or IA is 
not known.
Methods
Since 2006, 30 consecutive patients received three standard postoperative IAs. 
Starting from 2009, the last 46 patients received only preoperative IA. Preoperative 
desensitization consisted of rituximab, tacrolimus, mycophenolate mofetil, prednisone 
and intravenous immunoglobulins. Antigen-specific IA was performed pre-operatively 
with the Glycosorb® device. Biopsy-proven acute rejections either antibody-mediated 
(AMR) or mixed cellular and antibody-mediated (MAR) within three months were 
recorded.
Results
The postoperative titer in patients with postoperative IA did not exceed 1:16 (IgG 1:4 
[<2-16] median and range). The postoperative IgG titer was not significantly different 
after abandoning postoperative IA, although three patients had titers of 1:32 and 
one patient even 1:128. Rejections tended to be more frequent in the group with 
postoperative IA: 6 AMR and 3 MAR were recorded in 30 patients, versus 4 AMR and 
1 MAR in the 46 patients without postoperative IA (30 vs. 11%, p=0.067). Baseline 
characteristics differed however: in the group with postoperative IA the vast majority 
had blood group O (87 vs. 52%, p=0.003). Also the IgG titer on the day of transplantation 
was higher (1:4 [<2-16] vs. 1:2 [<2-32], p=0.007). All 14 patients with AMR and MAR 
rejections had postoperative IgG titers ≤1:16.
Conclusion
Postoperative removal of A/B antibodies can be safely removed from the ABOi 
transplantation protocol using strict preoperative criteria for antibody lowering.
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INTRODUCTION
Thirty years after the first deliberate ABO-incompatible kidney transplantations were 
performed, protocols to cross ABO blood group barriers differ substantially across 
centers worldwide (1). The cornerstone of these different programs is the reduction of 
A/B antibodies at time of transplantation by plasmapheresis. Different plasma exchange 
approaches are applied: “classical” plasma exchange is performed in most centers in the 
United States (2, 3) and Australia (4), while double-filtration plasmapheresis aiming at 
specifically removing the immunoglobulin fraction is a common procedure in both Japan 
and Europe (5). Many European centers use antigen-specific immunadsorption (IA) 
with synthetically derived blood group A or blood group B columns (6), but experience 
with non-antigen-specific IA, such as protein A and polyclonal sheep antihuman IgG 
antibodies is mounting (7, 8).
Originally, a standard number of postoperative plasma exchange sessions were 
performed to sustain the lowered A/B antibody titers in the first 2 weeks after 
transplantation, as this was believed to be important for the prevention of antibody-
mediated rejection. For example, the Stockholm protocol as described by Tydén 
provided for three standard postoperative IA sessions, and if the A/B antibody titer 
rose two dilutions, another postoperative IA session was scheduled (6). However, the 
need for postoperative antibody removal strategies is a matter of debate. The Freiburg 
group was the first to abandon pre-emptive postoperative IA: only if the postoperative 
IgG titer reached a certain threshold, >1:8 in the first postoperative week or >1:16 in 
the second, then postoperative IA sessions were scheduled (9, 10). This “on-demand” 
protocol did not seem to result in more rejection (9) and has been adapted by others 
lowering the postoperative threshold to >1:8 (11-13) and even >1:32 (7) to initiate IA. 
In our center, we started ABO-incompatible kidney transplantation in 2006, applying 
the original Stockholm protocol. An interim analysis after 30 transplantations showed 
that postoperative A/B antibody titers remained low and we did not find an association 
between titers and rejection (14). Therefore, we decided to stop postoperative IA. 
In this report we compare the outcomes of the first cohort of patients treated with 




We analyzed all consecutive recipients of a blood group ABOi kidney transplant between 
March 2006 and September 2014 in the Erasmus Medical Center in Rotterdam, the 
Netherlands (n=76). In short, the regimen included rituximab 375 mg/m2 4 weeks 
before transplantation; tacrolimus 0.1 mg/kg BID, mycophenolate mofetil 1000 mg BID; 
prednisone 20 mg once daily starting two weeks before transplantation and intravenous 
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immunoglobulins 0.5 g/kg one day preoperatively. Antigen-specific IA was performed 
preoperatively in all but three ABOi recipients. Plasmapheresis was performed with a 
plasmaFlux PSu filter (Fresenius Medical Care, Bad Homburg, Germany) followed by 
adsorption of A/B antibodies with the Glycosorb® device, coated with synthetically 
derived blood group A or blood group B antigen (Glycorex Transplantation, Lund, 
Sweden). In 4 hours, 1.5 L plasma/hour was led over the column, using unfractionated 
heparin infusion 1000 U/hour to prevent clotting. The first 30 patients additionally 
received postoperative IA as per protocol, performed on days 3, 6 and 9 (or days 2, 5 
and 8 depending on the day of surgery). Starting in December 2009, the last 46 patients 
received only preoperative IA. The postoperative immunosuppressive regimen after 
transplantation consisted of tacrolimus 0.1 mg/kg BID, mycophenolate mofetil 1000 
mg BID, prednisone 50 mg BID for three days and 20 mg once daily thereafter in all 
patients.
Determination of antibody titers
Our procedure to determine hemagglutinin titers has been described in detail before 
(14). In short, red blood cells of the donor were used to determine IgG and IgM titers 
against donor ABO-blood group using the fully automated ORTHO BioVue system 
column agglutination technology. The titer before IA was defined as the highest titer 
within one month before transplantation. The titer on the day of transplantation was 
determined on the morning of transplantation, one day after the last preoperative IA 
(allowing for antibody rebound). The postoperative titer was defined as the highest 
titer during two weeks postoperatively.
Data collection
Biopsy-proven acute rejections either antibody-mediated (AMR) or mixed cellular and 
antibody-mediated (MAR) within three months according to revised Banff ’09 criteria 
were recorded (15). Biopsies were taken for cause when kidney function deteriorated 
without an alternative explanation. Renal function at month 12 was documented.
Statistics
For analysis the patients were divided into the postoperative IA group (n=30) and the 
non-postoperative IA group (n=46). Data were analyzed using GraphPad Prism version 
6.0 and the Mann-Whitney U-test was used to determine differences between groups. 
The statistical significance level was determined as p ≤0.05.
RESULTS
Baseline characteristics
Initial titers of ≤1:256 were accepted for enrollment in the desensitization program, 
although one exception was made in a patient without postoperative IA with an initial 
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IgG titer 1:512. The target IgG titer after the last IA was <1:8. Baseline characteristics 
differed between groups. In the group with postoperative IA the vast majority had blood 
group O (87 vs. %, p=0.003, table I). The titer the day of transplantation was higher in the 
group with postoperative IA (median IgG 1:4 [<2-16] vs. 1:2 [<2-32], p=0.007, and IgM 1:2 
[<1-16] vs. 1:1 [<1-16], p=0.005, Table 1). The number of HLA mismatches on A, B and DR 
loci, peak PRA and the number of previous kidney transplantations were comparable.
Rejection episodes
Rejections were non-significantly more frequent in the group with postoperative IA: 
6 AMR and 3 MAR were recorded in 30 patients, versus 4 AMR and 1 MAR in the 46 
patients without postoperative IA (30 vs. 11%, p=0.067, Figure 1). Treatment consisted 
of pulse methylprednisolone and IVIG; extra IA was performed only in the group with 
postoperative IA. One patient was also treated with rATG because of insufficient renal 
function recovery. One patient with AMR Banff type 3 underwent transplantectomy 
(16).
Table 1. Baseline characteristics of ABOi recipients with versus ABOi recipients without 
postoperative antigen-specific immunoadsorption.
postoperative IA only preoperative IA p-value
recipients (number) 30 46 -
blood group O 26 (87%) 24 (52%) **





























age recipient (mean) 49 54 n.s.
no. of preop IA 4 (2-7) 3.5 (0-10) n.s.
no. of postop IA 3 (1-8) - -
no. of kidney transplantations 1.17 (0.07) 1.24 (0.08) n.s.
peak PRA%, median (range) 4 (0-75) 4 (0-85) n.s.
HLA mismatches on A, B, DR loci, mean (SEM)
 MM on A
 MM on B










IgG before IA, median (range) 32 (<2-128) 16 (<2-512) n.s.
IgM before IA, median (range) 32 (<1-128) 16 (<1-256) n.s.
IgG the day of transplantation, median (range) 4 (<2-16) 2 (<2-32) *
IgM the day of transplantation, median (range) 2 (<1-16) 1 (<1-16) **
IA: immunoadsorption PRA: panel reactive antibodies HLA: human leucocyte antigen
* p ≤0.05 ** p ≤0.005 *** p ≤0.0005
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Figure 1. Antibody-mediated and mixed cellular and antibody-mediated rejection in ABO-incompatible 
kidney transplant recipients treated with and without postoperative immunoadsorption.
A.     B.










































with postop IA: ABO-incompatible kidney transplant recipients treated with preoperative and standard 3 postoperative 
immunoadsorption sessions.
without postop IA: ABO-incompatible kidney transplant recipients treated with preoperative immunoadsorption only. 
AMR: antibody-mediated rejection      MAR: mixed cellular and antibody mediated rejection
Figure 2. Highest postoperative A/B antibody titers day 1 to day 14. Postoperative IgG titers were com-
parable between recipients with and without postoperative immunoadsorption, while postoperative IgM 
titers were slightly higher after abandoning postoperative IA (A). When comparing recipients with rejection 
and those without rejection, no significant association between postoperative immunoadsorption and 
rejection could be observed (B).
Anti-A/B titers
The postoperative titer in patients with postoperative IA did not exceed 16 (IgG 1:4 
[<2-16] and IgM 1:4 [<1-16], Figure 2A) and there was no net change in postoperative 
titers versus titers the day of transplantation (change in dilution step median 0 [minus 
2 - plus 3], data not shown). After abandoning postoperative IA, the postoperative 
titer was available for 23 patients. The median postoperative IgG titer of these 23 
patients did not differ compared to the group with postoperative IA. Three patients 
had titers of 1:32 and one patient even 1:128 (median IgG 1:4 with postoperative IA 
AMR: antibody-mediated rejection   
MAR: mixed cellular and antibody-mediated 
rejection
postop IA: patients with antigen-specific postop-
erative immunoadsorption
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vs 1:8. without postoperative IA, p=0.62, Figure 2A). Postoperative IgM titers were 
slightly higher after abandoning postoperative IA (IgM 1:4 [<1-16] with postoperative 
IA vs 1:4 [<1-64] without, p=0.04). When comparing patients with rejection (AMR and 
MAR) and those without rejection, no significant association between postoperative IA 
and rejection could be observed. Of the 14 patients experiencing biopsy-proven acute 
rejection, 11 postoperative titers were available and none exceeded 16 (Figure 2B).
Renal function
Twelve month follow-up was available for 26 patients in the postoperative IA group: 2 
patients had died (suicide and abdominal sepsis) and two grafts failures occurred (month 
3 ongoing rejection and month 4 intractable AMR during Gram-negative sepsis (16)). 
35 patients without postoperative IA had one-year follow-up. No death or graft loss 
occurred within this group. Creatinine levels were comparable between groups (145.5 




































Figure 3. Kidney function one year follow-up. One year after transplantation, kidney function was similar in 
ABO-incompatible kidney transplant recipients treated with and without postoperative immunoadsorption.
DISCUSSION
Changing the original Stockholm protocol to an ABO-incompatible kidney transplantation 
program without postoperative IA does not lead to more rejection episodes and does 
not affect renal graft function at one year follow-up. Postoperative titers did not 
predict acute rejection episodes: the 14 patients who did experience a biopsy-proven 
acute rejection within three months had postoperative A/B-titers not exceeding 16. 
Postoperative IA therefore seems to be an unnecessary procedure, at least in a protocol 
with initial IgG titers of ≤1:256 and a target titer after the last IA of <1:8.
postop IA: ABO-incompatible kidney trans-
plant recipients treated with preoperative 
and standard 3 postoperative immunoad-
sorption sessions.    
IQR: interquartile range
only pre-op IA: ABO-incompatible kidney 
transplant recipients treated with pre-
operative immunoadsorption only.
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The safety of abandoning standard postoperative IA has been demonstrated in titers 
remaining below 16 (9). The uneventful clinical course in our cohort without rejection 
in 5 patients with postoperative IgG titers of 1:16 and in 4 patients with 1:32 or even 
higher however, is in contradiction with outcomes in Japanese and American patients 
treated with preoperative PE or splenectomy, of whom postoperative titers exceeding 
1:16 correlated with rejection (17-19). However titers are not one-to-one comparable 
between centers (20).
The retrospective analysis of our cohort has overt limitations. After abandoning 
postoperative IA, titer measurements were only performed in 23 out of 46 patients. 
However, the postoperative titers in the group without postoperative IA were in a 
similar range as the postoperative titers in the group with postoperative IA. Secondly, 
the cohort of patients with standard postoperative IA experienced more AMR and MAR 
than reports of other centers using the Stockholm protocol (21). As described before 
we could not fully explain this discrepancy (14), although baseline characteristics reveal 
in this first cohort a higher frequency of blood group O, associated with rejection (22). 
Third, our protocol has a cut-off entry titer of IgG ≤1:256 (one exception was made) and 
whether our findings can be extrapolated to higher initial titers is unclear.
Our data are in agreement with others (7, 9, 10) and indicate that circulating anti-
A/B antibodies after kidney transplantation are present and may increase, but their 
presence does not have to lead to AMR. This condition is termed accommodation 
but the underlying mechanisms are only partly understood and may include impaired 
A/B-antigen presentation in the donor organ or a decreased cytotoxic effect of A/B 
antibodies on renal endothelium (23-25). Finally, critical appraisal of postoperative PE/ 
IA is justified, since PE/IA may lead to a higher rate of infection and bleeding observed 
after ABOi kidney transplantation (26-29).
In conclusion, postoperative removal of anti-A/B antibodies can be safely removed 
from the ABOi transplantation protocol using strict preoperative criteria for antibody 
lowering.
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The major challenge in ABO-incompatible transplantation is to minimize antibody-
mediated rejection. Effective reduction of the anti-ABO blood group antibodies at the 
time of transplantation has made ABO-incompatible kidney transplantation a growing 
practice in our hospital and in centers worldwide. ABO antibodies result from contact 
with A- and B-like antigens in the intestines via nutrients and bacteria. We demonstrate 
a patient with fulminant antibody-mediated rejection late after ABO-incompatible 
kidney transplantation, whose anti-A antibody titers rose dramatically following Serratia 
marcescens sepsis.
Case presentation
A 58-year-old woman underwent an ABO-incompatible kidney transplantation for 
end-stage renal disease secondary to autosomal dominant polycystic kidney disease. 
It concerned a blood group A1 to O donation. Pre-desensitization titers were 64 for 
anti-blood group A IgM and 32 for anti-blood group A IgG titers. Desensitization 
treatment consisted of rituximab, tacrolimus, mycophenolate mofetil, corticosteroids, 
immunoadsorption and intravenous immunoglobulines. She was readmitted to our 
hospital 11 weeks after transplantation for S. marcescens urosepsis. Her anti-A IgM 
titer rose to >5000 and she developed a fulminant antibody-mediated rejection.
We hypothesized that the (overwhelming) presence in the blood of S. marcescens 
stimulated anti-A antibody formation, as S. marcescens might share epitopes with blood 
group A antigen. Unfortunately we could not demonstrate interaction between blood 
group A and S. marcescens in incubation experiments.
Conclusion
Two features of this post-transplant course are remarkably different from other reports 
of acute rejection in ABO-incompatible kidney transplantation: first, the late occurrence 
12 weeks after kidney transplantation and second, the very high anti-A IgM titers 
(>5000), suggesting recent boosting of anti-A antibody formation by S. marcescens.
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BACKGROUND
Both the HLA and the ABO blood group system determine the risk of rejection in 
clinical organ transplantation. The major challenge in blood group ABO-incompatible 
(ABOi) transplantation is to minimize antibody-mediated rejection (AMR). In recent 
years, ABOi kidney transplantation programs have been developed that minimize the 
risk for AMR and show excellent graft survival. The key to success has been effective 
reduction of the ABO antibodies prior to transplantation. This is usually achieved by 
repeated plasmapheresis with or without the use of a specific immunoadsorption 
procedure. A low concentration of ABO antibodies creates a window of opportunity 
for graft acceptance by an incompletely understood immunological phenomenon called 
“accommodation” (1,2). Within the first week after transplantation, AMR may occur but 
these can usually be effectively reversed by current standard AMR treatment protocols. 
Anti-ABO titers usually remain low after transplantation. ABO antibodies are traditionally 
referred to as “natural occurring”, since these antibodies were thought to occur without 
prior immunization. For over more than half a century, evidence is mounting that ABO 
antibodies most likely result from contact with A- and B-like antigens in the intestines 
via nutrients and bacteria, and develop early in childhood (3,4). Therefore, boosting of 
ABO antibody titers may occur by infections with Gram-negative bacteria (5) and could, 
at least theoretically, cause AMR of ABOi kidney transplants (6,7). We present a case 
of a late fulminant AMR of an ABOi kidney transplant which may have been triggered 
by Gram-negative bacteremia.
CASE PRESENTATION
A 58-year-old woman underwent living unrelated ABOi kidney transplantation. Her 
medical history revealed hypertension and autosomal dominant polycystic kidney 
disease, for which she had been on peritoneal dialysis. She had never been pregnant 
and never received any blood products. The donor kidney came from her 59-year-old 
husband and the HLA mismatch was 1-2-2 on A, B and DR loci respectively. She had 
no current or historical panel reactive antibodies. The donor blood group was A1 and 
the recipient’s was O. ABO desensitization treatment consisted of rituximab 375 mg/
m2 4 weeks before transplantation; tacrolimus 0.1 mg/kg BID, mycophenolate mofetil 
1000 mg BID; prednisone 20 mg once daily starting two weeks before transplantation 
and immunoglobulines 0.5 g/kg one day preoperatively. Five plasmapheresis sessions, 
followed by adsorption of anti-A antibodies with the Glycosorb® device coated with 
synthetically derived blood group A antigen, were performed in the week before 
transplantation. Her anti-A titer was 64 (IgM) and 32 (IgG) before treatment and 
decreased to 2 at the day before kidney transplantation. The surgical procedure was 
complicated by peri-transplant hematoma, for which erythrocyte concentrate and 
platelet transfusions were given (of blood group O donors). Immunosuppressive therapy 
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after transplantation consisted of tacrolimus 4 mg BID, mycophenolate mofetil 1000 
mg BID and prednisone 20 mg once daily. Valgancyclovir for cytomegolovirus (CMV) 
prophylaxis was started post-transplantation. Direct graft function was noted.
During admission, our patient experienced transient diarrhea and was treated for 
urinary tract infection with ciprofloxacin. Urine cultured Pseudomonas aeruginosa and 
Serratia (S.) marcescens (both > 105 colony forming units (cfu)). Before discharge, a 
routine biopsy on day 14 revealed normal renal parenchyma, with no signs of rejection. 
Staining for C4d on endothelial cells was positive, which is often seen after ABOi kidney 
transplantation and by itself does not indicate rejection. Anti-A titers remained low: 
one day postoperative the IgG titer was 2 and the IgM titer 8; at discharge, IgM titers 
were 1 and IgG titers were < 2. Renal function improved to a serum creatinine of 113 
μmol/l at time of hospital discharge.
Seven weeks post-transplantation, patient was readmitted for fever and loose 
stools. She had developed new onset diabetes mellitus, for which intravenous 
insulin was started. Abdominal ultrasound revealed a swollen transplant with signs 
of pyelonephritis with multiple micro-abscesses. A 10-day course of ceftazidime and 
ciprofloxacin was started for suspected pyelonephritis as the urine culture identified 
various uropathogens, not further specified.
Eleven weeks post transplantation, patient returned to our emergency department 
with fever, tachycardia and pain over the renal allograft. Serum creatinine had risen to 
115 umol/l with a C-reactive protein of 163 mg/l. Ultrasonography of the transplant 
kidney showed no gross abnormalities with normal renal vascular flow. Cultures of 
blood, urine and sputum were drawn and imipenem/cilastatine therapy was initiated. 
Only the blood culture became positive for S. marcescens sensitive to imipenem. In 
the next 5 days, serum creatinine increased further to 275 umol/l in combination 
with severe fluid retention. A newly obtained transplant ultrasound disclosed non-
measurable diastolic blood flow. On the clinical suspicion of rejection, a three-day 
course of methylprednisolone 1000 milligram intravenous was initiated and a transplant 
biopsy was performed. The kidney biopsy revealed AMR type 3 Banff ’09, with extended 
hemorrhagic infarction and positive C4d staining (Figure 1) (8). The anti-A IgM titer was 
>5000 and anti-A IgG titer 512. Transplantectomy was performed as a renal scintigraphy 
showed no perfusion. A swollen and hemorrhagic kidney transplant was removed and 
chronic intermittent hemodialysis was initiated. A repeated anti-A titer one month later 
was 256 for IgM and 32 for IgG (Figure 2).
EXPERIMENTS
We hypothesized that the (overwhelming) presence in the blood of S. marcescens 
stimulated anti-A antibody formation, as S. marcescens might share epitopes with blood 
group A antigen. We chose to perform a hemagglutination inhibition assay instead 
of direct (serum) agglutination with bacteria, as the latter could occur because of 
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possible aspecific clotting. S. marcescens obtained from the blood of our patient was 
frozen and stored until use. The thawed sample was plated on a (blood group free) 
Trypticase Soy agar (Becton Dickinson, USA) and grown at 37°C overnight. Cultures 
were suspended in phosphate buffered saline (PBS) and the concentration of bacteria 
in suspension was assessed using McFarland standards and plate counting the following 
day. Bacterial suspensions with concentrations ranging from 105 cfu/ml to 108 cfu/ml 
PBS and a PBS control were then either kept at 4 degrees Celsius, boiled, or sonicated. 
Subsequently, these different S. marcescens suspensions were incubated with anti-A 
plasma for 30 minutes at 37°C. Next, blood group A erythrocytes 4% (Sanquin blood 
supply, the Netherlands) were added and subsequently incubated for 15 minutes at 
room temperature. A PBS control was added to confirm visual agglutination after 
addition of A erythrocytes.
Figure 1. Kidney transplant biopsy 12 weeks after ABOincompatible kidney transplantation.
 A. Severe hemorrhage of the cortex and congestion of the glomeruli and tubulointerstitial compartment, 
with only minimal influx of inflammatory cells. There is a thrombus in the arteriole of the glomerulus. (H&E 
staining; original magnification 10x).
B. Congestion of the glomerulus with fibrinoid necrosis of the arteriole. There is ischemia of the tubuli. 
An artery shows a transmural inflammation, of both mononuclear cells and neutrophiles. (Periodic ac-
id-Schiff-Diastase stain; original magnification 20x).
C. Positive staining of more than 50% of the peritubular capillaries and all the glomeruli. (Immunohisto-
chemistry for C4d; original magnification 10x).
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Figure 2. Course of anti-A antibody titers before and after ABO-incompatible kidney trans-
plantation. The anti-A IgM (A.) and IgG (B.) titers were 64 and 32 respectively before pre-op-
erative immunoadsorption (December 13th), decreased to 2/2 pre-operatively (December 20th) 
and were 1/<2 at discharge. During AMR they increased to >5000/512, decreasing to 256/32
one month later (logarithmic scale).
We hypothesized that preincubation with a certain “threshold” amount of bacteria 
would prevent hemagglutination. We extrapolated this experimental design from the 
methods of Springer et al. who demonstrated interaction between Gram-negative 
bacteria and anti-ABO antibodies in 1961 (9) (see Discussion for more details). Antibody 
titer changes were investigated as well: after centrifugation the supernatant was stored 
at 4°C and anti-A titers were measured the following day by adding A erythrocytes in 
serial plasma dilutions and compared to the original titer. Titers were described as the 
highest dilution at which hemagglutination was still visible.
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We also performed experiments of bacterial incubation with human serum without 
addition of A erythrocytes, before measuring a possible change in titer the following 
day. In a parallel experiment, incubation with anti-A plasma took place for 2 hours at 
room temperature (for IgM binding).
RESULTS
In the first experiment serum was pre-incubated with unboiled bacterial suspensions 
in increasing concentrations. After addition of blood group A erythrocytes however, 
agglutination was still observed. As pre-incubation with viable bacteria did not result in 
inhibition of hemagglutination, i.e. did not absorb antibodies from the serum, we also 
measured a possible change in antibody titers. The original titer was diluted threefold 
with bacterial suspension and A erythrocytes in a 1:1:1 ratio. However, compared to 
the PBS control, pre-incubation with bacterial suspensions did not lower the titer of 
anti-A plasma when A erythrocytes were added.
Subsequently bacterial suspensions were boiled for 2.5 hours to unmask antigens 
that theoretically may have been hidden by the bacterial capsule. IgM titers were 
reduced but only one-fold, which was regarded as non-significant. When a surplus of 
bacterial suspension (4.8 × 10e9 cfu/ml) was added, agglutination was still present. In 
the last set of experiments, bacterial suspensions were boiled and centrifuged at higher 
speed (14000 rpm) than the previous experiment to prevent loss of light antigens, or 
sonicated to prevent denaturation of antigens. Similar amounts of bacterial suspension 
were incubated with or without A erythrocytes. However, both boiling and sonication 
did not prevent agglutination compared to PBS control.
DISCUSSION
We demonstrate a patient with fulminant antibody-mediated rejection after ABOi kidney 
transplantation, whose anti-A IgM titers rose dramatically following S. marcescens 
sepsis.
Two features of this post-transplant course are different from other reports of acute 
rejection in ABOi kidney transplantation: first, the late occurrence of AMR 12 weeks 
after kidney transplantation and second, the very high anti-A IgM titers (>5000).
Long term patient survival has not been shown to be significantly different between 
ABO-compatible and incompatible kidney transplant recipients (10). However, a higher 
risk of AMR exists, occurring mainly in the direct postoperative period. In the 51 patients 
with detailed time of onset of AMR in the literature, only 4 experienced AMR 12 weeks 
or later after transplantation (11-19). Of all the 65 recipients of an ABOi kidney allograft 
in our center so far, 9 experienced AMR and 3 a combined AMR and cellular rejection, 
all within three months except for the patient presented in this case report (20). The 
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pathological role of anti-ABO IgG versus IgM on the ABOi renal allograft is a matter 
of debate (7,12,21). Takahashi hypothesizes on two distinct types of AMR after ABOi 
kidney transplantation: he states that type I AMR is caused by re-sensitization due to 
ABO-blood group antigens, occurs early postoperatively and is characterized by an 
IgG antibody rise. Type II AMR on the contrary is caused by primary sensitization due 
to ABO-blood group-associated antigens. IgM titer rises more than IgG and it takes 
longer for this type of AMR to develop (7). He accompanies this hypothesis with two 
examples: A 34-year-old blood group O recipient receiving a blood group B renal 
allograft, experienced an AMR on postoperative day 19 during urosepsis with Klebsiella 
pneumonia. IgM rose from 4 to 64 and IgG from < 2 to 4. The second example is a 
68-year-old male blood group B recipient who received a blood group A renal allograft. 
On postoperative day 9 his graft was removed because of an untreatable AMR in the 
presence of Methicillin-resistant Staphylococcus epidermidis pneumosepsis. His IgM 
titer rose from 2 to 512 and IgG remained < 2 during the clinical course. We therefore 
hypothesized that also this AMR had a different etiology than re-sensitization by blood 
group A antigens: a Gram-negative sepsis.
ABO antibodies are not “naturally occurring” and result from contact with A- and 
B-like antigens in the intestines via nutrients and bacteria (3,4). ABO antibodies are either 
absent at birth or present via placental transfer and breastfeeding. Before the age of 3, 
the infant’s gut becomes colonized with commensal bacteria expressing A- and B-like 
antigens. The developing immune system produces antibodies against the antigens 
not present on its own erythrocytes. The continuing influence of gut bacteria on ABO 
antibody formation is reflected in permanent detectable IgM titers, for example the 
IgM titers measured in kidney transplant recipients before ABOi kidney transplantation. 
In 1969 Springer and Horton fed 23 very young infants (35 weeks or younger) and 14 
adults killed Escherichia coli O86 (4). It concerned blood group A and O individuals, both 
healthy subjects as well as patients with intestinal disorders: 16 children with diarrhea, 
2 adults with ulcerative colitis and 2 adults with colon carcinoma. The majority had a 
fourfold or greater increase in anti-B antibodies after ingestion, infants more than adults 
and diarrheic patients more than healthy controls. Moreover, six out of seven infants 
without a baseline titer had titers of 16 or greater after ingestion. In the same paper, 
Springer demonstrated that anti-human blood group A and B antibodies in chickens 
can be neutralized by injecting live Escherichia coli O86.
Many Gram-negative bacteria with human blood group activity are identified. For 
example Yi sequenced the entire Escherichia coli O86 gene cluster and identified all the 
genes responsible for the blood group B-like antigen biosynthesis (22).
There is more evidence that bacterial suspensions are able to reduce anti-ABO titers 
by binding these ABO antibodies to the bacteria: Springer et al. assessed the blood 
group activity of 282 Gram-negative bacteria (9). Different bacterial suspensions were 
incubated with series of human serum with minimal 4 agglutination titers for two hours. 
Almost 50 percent of these 282 strains exhibited anti-ABO activity. Bacteria with only 
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one specificity far outnumbered those with two or all three ABO specificities, in which 
anti-O and anti-B were predominant.
Strong evidence that gut bacteria are able to trigger ABO antibody formation is 
reported by Daniel-Johnson et al. (23). He describes severe hemolytic transfusion 
reactions in two blood group B recipients of a blood group A platelet donor. Although 
platelet transfusion is preferably performed ABO identical or at least blood group 
compatible, the limited availability of matched platelet donors makes platelet donation 
across ABO barriers a common practice. This is infrequently followed by hemolysis as 
only a small amount of (ABOi) donor plasma is present. In contrast, in the blood group A 
platelet donor described by Johnson et al., the anti-B IgG titer rose to 16384 after taking 
three tablets of probiotics per day. Furthermore, the solubilized form of this probiotic 
was found to be able to reduce the measured anti-B in plasma of a randomly chosen 
blood group A donor threefold, from 64 to 8 after incubation at room temperature in 
vitro.
In ABOi solid organ transplantation the relation between sepsis and AMR is also 
reported. A pediatric ABOi kidney transplant recipient experienced biopsy-proven 
AMR during pyelonephritis, with an increase in anti-B titers to 64 and 128 for IgG and 
IgM, respectively (6). Oya et al. report on an ABOi living donor liver transplantation 
with an anti-B titer rise during an intra-abdominal hematoma infected with Serratia 
marcescens. Subsequently thrombotic microangiopathy developed. The authors suggest 
that interaction between the anti-donor ABO antibodies and the endothelial cells of the 
graft played a causative role in this microangiopathy (24). Unfortunately, in our case, we 
could not demonstrate an anti-A antibody binding capacity of the S. marcescens strain 
isolated from our patient. There are several possible explanations for this. First, the 
Serratia colonies grew rather mucoid which is an indication of a capsule. The capsule 
might have been impermeable to ABO antibodies. However, even boiling which has 
been presumed to remove the capsule, or sonication to unmask the bacterial cell wall 
expressing other antigenic epitopes, did not change the results. Second, the amount 
of bacteria might have been insufficient. However, we also performed incubation 
with a very viscous density without a change in titer. Third, assay temperature might 
play a role. However, temperature was adjusted for IgM antigen binding to room 
temperature and for IgG antigen binding to 37°C and this did not result in inhibition of 
agglutination. Fourth, the time for interaction between anti-A antibodies and bacterial 
epitopes and subsequently with A erythrocytes was shorter than in the experiments 
carried out by Springer. In addition, Springer and Horton describe in their methods the 
possibility of “non-agglutinating-in-saline” ABO antibodies and their detection with 
anti-human serum after immunizing chickens with ABO antigens. We did not explore 
this possibility.
Next to S. marcescens sharing a comparable epitope with antigen A, another 
explanation for the development of antibody-mediated rejection during S. marcescens 
sepsis exists. This might be a change in antigenicity of the A antigen. S. marcescens 
was cultured in our patient’s urine several times and subsequently in her blood. S. 
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marcescens is a Gram-negative bacillus and belongs to the family of Enterobacteriaceae 
(25). Mannose-sensitive pili of S. marcescens are known to stimulate renal scarring (26). 
This renal scarring could have hypothetically enhanced changes in ABO antigenicity in 
the kidney graft.
Conclusion
ABO antibodies result from contact with gut bacteria. A Gram-negative sepsis could 
theoretically boost anti-ABO antibody formation. We demonstrated a patient whose 
anti-A titers rose dramatically after Gram-negative sepsis, leading to a type 3 antibody-
mediated rejection. Despite comparable incubation experiments in the literature, we 
could not demonstrate an interaction between S. marcescens and anti-A antibodies. 
Therefore it remains uncertain whether bacteremia can be the cause of antibody-
mediated rejection in ABOi kidney transplantation.
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Chapter 8
Summary and conclusions.




The overall aim of studying ABO-incompatible (ABOi) kidney transplantation is to 
improve outcomes for recipients of a kidney allograft. The studies presented in this 
thesis investigated the risk of ABOi kidney transplantation. Specifically, the benefits and 
risks of specific desensitization elements were described, and the status of ABOi kidney 
transplantation compared to ABO-compatible (ABOc) donation was investigated.
In chapters 2 and 6 we compared outcomes of ABOi kidney transplant recipients 
with ABOc recipients. We performed a systematic review of all single center studies of 
ABOi kidney transplantation with a control group of ABOc living donor transplantations 
from the same hospital (chapter 2). Our meta-analysis revealed slightly inferior graft 
and patient survival compared to recipients of an ABOc allograft with similar baseline 
characteristics: for every 100 transplanted recipients, after one year 96 patients are 
alive with a functioning ABOi allograft versus 98 alive patients with a functioning ABOc 
allograft (4 vs 2 graft losses). Half of the reported causes of death in ABOi patients 
were of infectious origin, versus only 13% in ABOc patients. The observed lower graft 
survival was irrespective of induction therapy, region, era and filtration technique. 
Antibody-mediated rejection, severe non-viral infection, and bleeding were also more 
common after ABOi transplantation. To counsel incompatible donor-recipient pairs on 
outcomes after ABOi transplantation, information on outcomes after deceased donor 
transplantation is also needed. Therefore, in chapter 6 all consecutive Dutch ABOi 
kidney transplant recipients were compared to matched deceased donor as well as 
living donor ABOc recipients. Patient survival after ABOi kidney transplantation was 
superior to deceased-donor controls (HR for death 0.67 [95%CI 0.48-0.92] in ABOi 
vs ABOc deceased donor recipients). Graft survival in the total ABOi cohort however 
was no different from that among deceased donor ABOc recipients. Half of this ABOi 
cohort however was treated with rituximab alone induction and their outcomes trended 
towards inferior graft survival compared to combined B- and T-cell targeted induction 
therapy.
Chapters 3, 4 and 5 described analyses of the ABOi program at the Erasmus Medical 
Center.
In chapter 3 the first cohort of ABOi kidney transplant recipients was described 
in detail, with a focus on antibody-mediated rejection. For each of the first 50 ABOi 
allograft recipients, two ABOc living donor allograft controls were matched for 
period, recipient age and number of HLA mismatches. Antibody-mediated rejection 
was observed frequently, in 11 out of 50 ABOi patients. Five of these rejections were 
diagnosed as mixed cellular and antibody-mediated rejection at time of biopsy. This 
analysis led to reflections on the desensitization protocol and specifically the induction 
agent. The observed high frequency of rejection compared to the literature on this 
“Swedish” protocol (1, 2) led to a protocol change in 2015, in which rituximab was 
replaced by alemtuzumab (chapter 6).
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In chapter 4, the impression of clinicians treating ABOi transplant recipients 
that ABOi recipients “ooze easily” was substantiated. We analyzed the data of 65 
consecutive ABOi kidney transplant recipients and compared them to 130 control 
patients matched for age of donor and recipient in the period 2006-2013. Erythrocyte 
concentrate blood transfusion (EC) was administered more than twice as frequently in 
ABOi recipients in the first 48 hours after transplantation than in controls (29% vs 12% 
of patients). Both the number of patients needing blood transfusion and the number 
of ECs per transfusion were higher in the ABOi group, and more major bleeding was 
observed (15% vs 2% received ≥3 EC). The platelet count dropped significantly in ABOi 
recipients during desensitization resulting in 22% of ABOi recipients with a preoperative 
platelet count below 100 x109/L. Of note is that in ABOi patients 40% of blood group 
O recipients received EC versus 9% of non-blood group O recipients. However, only 
the number of immunoadsorptions (IA) correlated in multivariate analysis with the 
number of postoperative EC transfusions. An observed drop in hemoglobin level after 
desensitization likely played a role in the higher blood transfusion rate. On top of 
that, intraoperative blood loss was also significantly higher in ABOi recipients (544 vs 
355 ml). Traditional coagulation tests such as the aPTT and the PT-INR did not differ 
between ABOi and ABOc recipients. This finding of a higher risk of bleeding was also 
substantiated in the meta-analysis in chapter 2, irrespective of immunoadsorption 
versus plasmapheresis technique.
In chapter 5, we demonstrated that after abandoning postoperative IA the median 
postoperative anti-blood group titers remained low and similar compared to the group 
with standard three postoperative IA sessions (median highest two-week postoperative 
IgG titer of 4 vs 8 with and without postoperative IA). Furthermore, there was no 
correlation between the occurrence of rejection and blood group titers. Rebound of 
A/B antibodies was observed in some patients in the group without postoperative IA, 
resulting in titers of 32 and even 128, although this was in the absence of rejection. 
All five patients with (mixed cellular) antibody mediated rejection in the 46 patients 
without postoperative IA had postoperative titers of ≤16.
In chapter 6 different induction agents were compared in the Dutch national 
cohort of ABOi kidney transplant recipients. Of the 296 recipients described, the 
three commonly used regimens were rituximab (n=146), rituximab/basiliximab (n=50) 
and alemtuzumab (n=92). In this explorative analysis, baseline characteristics, such 
as transplant center and year of transplantation, differed. Alemtuzumab treated 
recipients were older, while rituximab treated recipients had longer dialysis vintage and 
preemptive transplantation was performed less frequently. Rituximab/basiliximab and 
alemtuzumab induction both trended towards better outcomes compared to rituximab 
induction alone (HR for graft failure compared to rituximab of 0.32 [95%CI 0.04-2.45] 
and 0.87 [95%CI 0.36-2.13] respectively). This may be driven by the lower rejection 
rates: 47% of rituximab vs 22% of rituximab/basiliximab vs 4% of alemtuzumab treated 
recipients experienced rejection in the first year (p <0.001). Renal function at year 
one was significantly better for both alemtuzumab and rituximab/basiliximab versus 
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rituximab treated recipients. Patient survival after ABOi kidney transplantation was 
similar in the three different regimens. As opposed to the high contribution of infection 
to death in the meta-analysis in chapter 2, only two of the reported 18 deaths (with a 
truncated follow-up of five years) were of infectious origin. Neither of the two infectious 
deaths were in the combined T- and B-cell directed regimens.
In chapter 7 an ABOi recipient was described who experienced a fulminant 
antibody-mediated rejection during a Gram-negative sepsis. Her anti-A titer rose 
to IgM >5000 and IgG 512. The onset at three months after transplantation and the 
exceptionally high titers led to the speculation that bacterial antigens led to boostering 
of her anti-A antibodies. We described evidence in the literature for this blood group 
antibody booster hypothesis. A platelet donor taking probiotics led to severe hemolytic 
transfusion reactions in two platelet recipients (3). The solubilized form of this probiotic 
could reduce blood group titers after incubation. In the 1960s, Springer fed bacterial 
suspensions to men and children and demonstrated a rise in their A/B titers (4). In 
our experiments with suspension of anti-blood group A plasma and A erythrocytes, 
preincubation with Serratia marcescens could not prevent hemagglutination. In the 
supernatant there were no antibody titer changes, so the booster hypothesis could not 
be substantiated in our experiments.
CONCLUSIONS
The studies in this thesis have shown that ABOi kidney transplantation using a living 
donor is superior to ABOc deceased donor transplantation. The inferior outcomes of 
ABOi compared to ABOc in living donor transplantation continue to be an incentive 
to invest in adequate donor selection and kidney exchange programs. ABOi kidney 
transplant recipients experienced more antibody-mediated rejection. This increased 
immunological risk is also reflected in the trend towards better allograft survival 
with combined T- and B-cell targeting than rituximab induction alone. Postoperative 
immunoadsorption is of no benefit in the prevention of antibody-mediated rejection. 
One of the benefits of limiting the number of immunoadsorption sessions is to avoid 
excess blood transfusions.
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Chapter 9
Discussion, future perspectives and 
recommendations.




One of the main goals of this thesis was to establish the risks and benefits of ABOi kidney 
transplantation versus ABOc and deceased donor kidney transplantation. Therefore, 
we performed a meta-analysis of all published comparative studies and evaluated in 
more detail the results of the national ABOi program.
Comparison with ABOc living donor and deceased donor transplantation
The meta-analysis in chapter 2 demonstrated slightly inferior patient and death-
censored graft survival after ABOi as compared to ABOc living donor transplantation 
(uncensored graft survival after one year of 96 vs 98% (RR 0.97, 95%CI 0.96-0.98). Scurt 
et al. published a meta-analysis on the same topic one year later and revealed worse 
outcomes than those described in our analysis (1): one-year patient survival of 96.9 vs 
97.8% in ABOi vs ABOc (OR 2.17 [95%CI 1.63-2.90]) and death-censored graft survival 
of 95.8 vs 95.0% (OR 2.52 [95%CI 1.8-3.54]). This study however was heavily criticized 
for using odds ratios instead of relative risks and for including overlapping patient 
populations leading to an overestimation of their findings (2, 3). As opposed to our meta-
analysis, Scurt et al. also included earlier reports before the introduction of rituximab 
when recipients underwent splenectomy to prevent antibody rebound. Interestingly, 
the supplemental material of Scurt et al. contained a subgroup analysis of rituximab 
versus no rituximab and revealed better outcomes for the rituximab group with death-
censored graft survival with OR 1.72 [95%CI 1.01-2.94] and remaining inferior patient 
survival as compared to ABOc with OR 1.97 [95%CI 1.14-3.42]. This underscores that 
splenectomy for ABOi kidney transplantation is obsolete (4). Despite the fact that ABOi 
kidney transplantation in the Netherlands has been performed without splenectomy, 
outcomes as described in chapter 6 were inferior to the outcomes described in the 
meta-analysis in chapter 2 (uncensored graft survival after one year in ABOi was 91.8% 
in the Dutch cohort versus 96% in the meta-analysis). The Dutch ABOc control recipients 
also had inferior outcomes as compared to the meta-analysis (uncensored graft survival 
after one year 95.7 versus 98%). The much higher patient and donor age of up to 10 
years in the Dutch cohort as compared to the meta-analysis is a likely explanation for 
the observed lower patient survival in both ABOi and ABOc. A possible contribution to 
the inferior outcomes in the Dutch cohort is the initial induction regimen with rituximab 
alone, as a trend towards inferior graft survival was observed for rituximab versus 
rituximab/basiliximab or alemtuzumab. Of the 26 studies in the meta-analysis, only one 
study, the original Swedish protocol, applied a regimen with rituximab only (5). Except 
for two studies with either ATG or basiliximab induction (6, 7) all other studies in the 
meta-analysis combined T-cell directed induction with rituximab. These observations 
strongly argue for the complementary role of an anti-T-cell agent in the induction 
regimen as discussed later in this section.
Despite a higher mortality in the first year after ABOi kidney transplantation as 
compared to propensity matched ABOc deceased donor recipients, patient survival 
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thereafter was superior (chapter 6). This is in line with a recent analysis of the United 
States Scientific Registry of Transplant Recipients (SRTR). Massie et al. demonstrated 
superior patient survival compared to matched waiting list candidates who received a 
(mostly deceased) donor transplant or remained on the waitlist, from 180 days post-
transplant onwards (8). Contrary to this study, we did not account for candidates dying 
on the waiting list while waiting for a deceased donor kidney transplant in the survival 
analysis. This immortal time bias in chapter 6 may reflect an underestimation of the 
benefical effect of ABOi kidney transplantation over (waiting for) ABOc deceased 
donor transplantation. We did perform a sensitivity analysis on dialysis vintage, which 
revealed a non-significant better patient survival after ABOi versus ABOc deceased 
donor transplantation (HR for death 0.82 [95%CI 0.59-1.14]).
The findings in the meta-analysis and the national cohort substantiate the choice of 
ABOi living donor kidney transplantation over ABOc deceased donor transplantation. As 
outcomes stay behind with ABOc living donor transplantation, they call for elaborate 
living donor transplant programs to increase options for ABOc living donor donation. 
These outcomes are also an incentive to address the elements of desensitization 
treatment in order to improve outcomes after ABOi kidney transplantation.
Antibody-mediated rejection
The results of this thesis show that antibody-mediated rejection is an obstacle after 
ABOi kidney transplantation as it occurred in 11 of the first 50 ABOi kidney transplant 
recipients at our center (chapter 3). Of note is that most of these rejection episodes 
(nine out of 11) took place in the first cohort of 25 recipients. Blood group O was 
overrepresented in this initial cohort (88%). The higher anti-A/B titers in blood group 
O recipients are a risk factor for ABMR and impact long-term graft survival after 
ABOi kidney transplantation (9-11). In the Dutch national cohort (chapter 6) a trend 
towards inferior outcomes for blood group O was also observed. The importance of the 
recipient blood group and titers limits external validation of findings in ABOi reports 
without blood group or titer information. The meta-analysis in chapter 2 however 
could not disclose blood group information as its purpose was to analyze outcomes for 
recipients of an ABOi kidney allograft as compared to receiving an ABOc allograft from 
the same center. This meta-analysis did reveal a high risk of ABMR after ABOi kidney 
transplantation versus ABOc living donor recipients. As PRA, DSA, retransplantation and 
HLA mismatches were comparable to ABOc control recipients from the same center, it is 
likely that the risk of ABMR could be attributed to the blood group incompatibility and 
not to “unchangeable” patient characteristics. Preoperative A/B titers are a risk factor 
for ABMR and graft loss (10). All ABOi desensitization protocols indeed recognize the 
importance of low preoperative IgG A/B titers and define target titers preoperatively. 
The comparison of these targets between centers, however, is limited by the different 
assays used for A/B titer measurement (12). Baseline and preoperative A/B titers 
seem to be more important for accommodation to occur than postoperative antibody 
removal (13, 14). The study in chapter 5 described that if preoperative titers are held 
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tight, postoperative antibody removal can be withheld in ABOi recipients. Although 
these findings have been substantiated in other reports (15, 16), Tobian et al. did find 
a correlation between postoperative titers and ABMR (17). 
Avoiding (postoperative) antibody removal is important as antibody removal 
leads to a higher blood transfusion rate (chapters 2 and 4). Other reports have also 
demonstrated the contribution of plasmapheresis to bleeding risks (18). At our center 
we have curtailed the number of IA sessions by increasing the plasma volume from 6 
to 12 liters (unpublished data, oral communication Dr. van Agteren). Different from 
rebound, accommodation could be disrupted by a booster production of antibodies. 
Chapter 7 described a recipient with an unusually late ABMR with very high IgM/
IgG titers and explored the possibility of a booster effect caused by a Gram-negative 
sepsis. Although data on bacterial induced booster production of A/B antibody exist 
(19, 20), we could not demonstrate that co-culture with the Serratia marcescens strain 
resulted in anti-A titer changes. Since reports on ABMR during sepsis after ABOi kidney 
transplantation are scarce, the theoretical breach of accommodation by bacteremia is 
not likely to be relevant in clinical practice.
So, establishing accommodation and avoiding ABMR is key in ABOi kidney 
transplantation, as the observed higher ABMR rate likely contributes to the higher 
mortality as observed in the meta-analysis.
Induction therapy
Another critical appraisal of desensitization is induction therapy. Rituximab has replaced 
splenectomy and is a key component in the majority of desensitization protocols. The 
Opelz registry demonstrated a trend towards inferior graft survival when rituximab 
was omitted (21). The dosage may be a matter of debate but the use of rituximab is 
widespread (22). The retrospective analysis in chapter 6 described a relatively large 
cohort of recipients treated with alemtuzumab (n=92). ATG is often administered in the 
United States instead of rituximab (6), whereas ATG has been combined with rituximab 
in France (23). The ABOi literature lacks randomized controlled trials comparing 
rituximab with other induction therapies. Given both the high risk of ABMR and the 
higher risk of infection (chapter 2), the major challenge in ABOi kidney transplantation is 
to administer induction therapy that prevents the need for rejection treatment without 
excessively compromising the infectious burden. The 3C study compared alemtuzumab 
to basiliximab induction in ABOc kidney transplant recipients and demonstrated that 
such a reduction in rejection episodes is feasible without an increase in infections 
(24). In this study, alemtuzumab led to a 58% proportional reduction in biopsy-proven 
acute rejections as compared to basiliximab, with serious infection rates of 32% in both 
groups. Alemtuzumab in the national ABOi cohort correlated with a strikingly low risk 
of rejection: only 4% of alemtuzumab treated recipients vs 47% of rituximab and 22% 
of rituximab/basiliximab treated recipients were treated for rejection in the first year 
after transplantation (p <0.001, chapter 6).
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To conclude, it is high time for a trial of induction treatment in ABOi kidney 
transplant recipients, keeping in mind the differences in methods of titer measurement 
and antibody removal protocols.
FUTURE PERSPECTIVES
Novel desensitization strategies
A promising desensitization agent is imlifidase, an IgG-degrading enzyme derived 
from Streptococcus pyogenes. It has shown promise in HLA-incompatible kidney 
transplantation through the rapid and complete removal of IgG from the blood (and 
tissue) within several hours (25). IgG started to recur after seven to 14 days. The 
question arises as to whether this cleaving agent can enable ABOi (deceased donor) 
kidney transplantation. A major obstacle is that imlifidase does not cleave IgM. 
A/B antibody IgM titers have a modest correlation with IgG and their relevance to 
ABOi kidney transplantation is not fully understood. Tierney et al. described seven 
consecutive A2 living donor kidney transplantations in non-immunized O recipients (PRA 
0%) with an IgG titer of <8 treated with depleting induction but without desensitization 
treatment (26). Four recipients had discrepantly high IgM titers ranging from 32 to 128 
of whom three experienced severe rejection. In the three patients with IgM titers of 4 
to 8, one recipient with an IgM titer of 4 experienced rejection. More reports suggest 
that IgM blood group antibodies are relevant in preventing AMR after ABOi kidney 
transplantation, in contrast to IgM antibodies against HLA molecules (27). Therefore 
the role of imlifidase may be limited to recipients with low IgM titers.
Accommodation
A different approach to lower the risk of antibody-mediated rejection after ABOi 
kidney transplantation is to lower the antigenicity of the incompatible kidney allograft. 
Tanabe et al. have investigated blood group antigen expression in kidney biopsies by 
immunohistochemistry in six ABOi kidney transplant recipients (28). Blood group antigen 
expression decreased to 64% after 10 years as compared to the implantation biopsy. 
In protocol biopsies of four ABOc control recipients blood group antigen expression 
remained stable at 99.8% after the same follow-up. Several theoretical options 
exist to impede the interaction of A/B antibodies and their corresponding antigens: 
these include reducing antigen expression by infusion of recombinant galactosidase 
enzyme (29) and neutralization of A/B antibodies (30). Although promising in in vitro 
experiments, so far these ideas have not been further investigated clinically.
Priority programs for ABO-incompatible kidney transplant candidates
For a kidney transplant candidate with an intended ABOi donor, the current policy in the 
Netherlands is to participate in the national kidney exchange program for two rounds, 
that is, six months. The success of this program is modest: of the 48 ABOi candidates 
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in this program in 2018, eight received an ABOc exchange allograft via this exchange 
program, 11 underwent ABOi kidney transplantation and seven were transplanted with 
a ABOc living donor outside the program (31). To improve the exchange rate for ABOi 
in such a program, either the pool can be enlarged or allocation rules can be adapted 
in favor of ABOi candidates. The first can be achieved by stimulating ABOc couples to 
voluntarily participate in exchange programs and by non-directed donation (32). The 
latter was simulated in a computer integrated allocation approach prioritizing immunized 
and blood group incompatible candidates (33): of 90 actual kidney transplantations 16 
were ABOi, whereas the simulated allocation resulted in 95 transplantations of which 
only five were ABOi. Blood group incompatibility could thus be circumvented in the 
majority of these recipients.
Allowing A2 incompatible (deceased donor) kidney transplantation
The kidney transplant candidate without a living donor is dependent on allocation 
programs for deceased donors (34). In the United States, transplantation of deceased 
donor blood types A2(B) is allowed for blood type B candidates with acceptable low 
(IgG ≤4) anti-A titers since 2014 (35). Outcomes after 560 A2 incompatible kidney 
transplantations appeared similar to ABOc transplantation in a retrospective United 
Network for Organ Sharing (UNOS) analysis (36). A simulation study in the United 
Kingdom permitting A2 donation resulted in more HLA 0-0-0 mismatched donor kidneys 
and shorter waiting times for B recipients (37).
RECOMMENDATIONS
The studies in this thesis have investigated desensitization treatment for ABOi kidney 
transplantation. Its findings have the following clinical implications:
- Invest in an elaborate living kidney donation program to enable chances of finding 
an ABO-compatible living donor in due time (chapters 2 and 6).
- In the absence of an ABOc living donor, when an ABOi donor is available, proceed 
with ABOi kidney transplantation instead of deceased donor transplantation 
(chapter 6).
- Be prepared for the higher bleeding risk in ABOi recipients (chapters 2 and 4). 
Desensitization results in an average fall in hemoglobin level of 0.55 mmol/L and 
more intraoperative blood loss (chapter 4).
- Abandon postoperative immunoadsorption (chapter 5).
- The higher risk of (antibody-mediated) rejection should guide induction therapy to 
optimize outcomes after ABOi kidney transplantation (chapters 3 and 6). Combined 
T- and B-cell targeted therapy likely results in better outcomes than rituximab 
induction alone.
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- Outcomes after ABOi kidney transplantation should be interpreted in the context 
of recipient blood group (O versus non-O) (chapters 3 and 6).
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Het doel van het bestuderen van bloedgroep ABO-incompatibele (ABOi) 
niertransplantatie is het verbeteren van uitkomsten voor niertransplantatie patiënten. 
In de studies van dit proefschrift hebben we de risico’s van ABOi niertransplantatie 
onderzocht. De voor- en nadelen van specifieke onderdelen van de desensibilisatie 
behandeling werden geanalyseerd, alsmede de status van ABOi niertransplantatie in 
verhouding tot andere vormen van niertransplantatie.
In hoofdstuk 2 en 6 hebben we uitkomsten vergeleken van ontvangers van een ABOi 
niertransplantaat met ontvangers van een ABO-compatibel (ABOc) niertransplantaat. 
We hebben systematisch alle studies geanalyseerd die zowel de ABOi als de ABOc 
niertransplantaties uit hetzelfde centrum in dezelfde tijdsperiode  bestudeerd hebben 
(hoofdstuk 2). Deze meta-analyse liet zien dat ABOi ontvangers een iets slechtere 
patiënt- en transplantaatoverleving hebben dan vergelijkbare ABOc ontvangers: voor 
elke 100 transplantaties bleken na één jaar in deze meta-analyse 96 ABOi ontvangers 
in leven met een functionerend niertransplantaat, vergeleken met 98 ABOc ontvangers 
(4 versus 2 transplantaat verliezen). Van de gerapporteerde doodsoorzaken na 
ABOi niertransplantatie bleek de helft een infectieuze oorzaak te betreffen, versus 
slechts 13% na ABOc niertransplantatie. De slechtere transplantaatoverleving bleek 
onafhankelijk van inductietherapie, regio, periode en het gebruik van plasmaferese 
versus immunoadsorptie. Antistof-gemedieerde afstoting, ernstige (niet-virale) infecties 
en bloedingen kwamen ook meer voor na ABOi niertransplantatie. Voor adequate 
informatieverstrekking aan incompatibele koppels zijn deze bevindingen relevant. 
Het is echter voor deze voorlichting ook belangrijk om naast de vergelijking met ABOc 
levende donor niertransplantatie, ook de vergelijking met ABOc overleden donor 
niertransplantatie te maken.
Daartoe werden in hoofdstuk 6 alle Nederlandse ABOi niertransplantatie ontvangers 
vergeleken met zowel ‘gematchte’ ABOc overleden donor als ‘gematchte’ ABOc levende 
donor ontvangers. De patiëntoverleving na ABOi niertransplantatie was beter dan na 
ABOc overleden donor niertransplantatie (hazard ratio (HR) voor overlijden 0.67 [95%CI 
0.48-0.92] in ABOi versus ABOc overleden donor ontvangers). De transplantaatoverleving 
na ABOi niertransplantatie verschilde niet van die na ABOc overleden donor 
niertransplantatie. De helft van deze ABOi niertransplantatie ontvangers was behandeld 
met rituximab inductie, en van hen neigde de transplantaatoverleving  naar matigere 
uitkomsten dan van hen die behandeld werden met gecombineerde T- en B-cel 
inductie.
Hoofdstukken 3, 4 en 5 bevatten studies over het ABOi programma van het Erasmus 
Medisch Centrum (MC).
De eerste 50 ABOi niertransplantatie ontvangers van het Erasmus MC werden 
beschreven in hoofdstuk 3, met een analyse van het optreden van antistof-gemedieerde 
afstoting. Voor deze analyse werd elke ABOi ontvanger uit dit eerste cohort van 50 
‘gematcht’ met 2 ABOc levende donor niertransplantatie ontvangers. Deze ‘matching’ 
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oftewel koppeling gebeurde op basis van het jaar van transplantatie, de leeftijd van 
de ontvanger en het aantal humaan leucocytenantigenen (HLA) mismatches. Antistof-
gemedieerde afstoting kwam vaak voor, namelijk bij 11 van de 50 ABOi ontvangers. Vijf 
van deze 11 afstotingen vertoonden in het biopt tekenen van een gemengd cellulaire en 
antistof-gemedieerde afstoting. Deze bevindingen vormden aanleiding tot reflectie op 
het gehanteerde inductieprotocol. Het frequent optreden van afstoting, waaronder ook 
cellulaire afstoting, zeker in vergelijking met andere publicaties over dit Zweedse ABOi 
protocol (1,2), was aanleiding tot aanpassing van het protocol. In 2015 werd rituximab 
(anti-CD20, depletie van B-cellen) als inductietherapie vervangen door alemtuzumab 
(anti-CD52, depletie van T, B en NK cellen) (hoofdstuk 6).
Het idee onder clinici dat tijdens ABOi niertransplantatie moelijker hemostase 
bereikt kon worden, werd onderzocht in hoofdstuk 4. Daartoe hebben we de eerste 
65 ABOi ontvangers in het Erasmus MC vergeleken met 130 ABOc ontvangers, 
‘gematcht’ voor leeftijd van de donor en van de ontvanger in de periode 2006-2013. 
Bloedtransfusie in de eerste 48 uur vond meer dan twee maal zo vaak plaats na ABOi 
dan na ABOc niertransplantatie (29% vs 12%). Zowel het aantal ontvangers dat een 
bloedtransfusie nodig had, als het aantal eenheden erytrocyten concentraat (EC) dat 
per transfusie gegeven werd, was hoger in ABOi ontvangers. Dit gold eveneens voor 
het optreden van ‘majeure bloeding’, hier gedefinieerd als  ≥3 ECs (15% vs 2% in ABOc). 
De trombocyten (bloedplaatjes) daalden significant tijdens desensibilisatie voorafgaand 
aan ABOi niertransplantatie, resulterend in 22% van de ABOi ontvangers met een 
preoperatief trombocyten getal van <100 x109/L. Een opvallende bevinding was dat 40% 
van de ontvangers met bloedgroep O een bloedtransfusie onderging, in tegenstelling 
tot slechts 9% van de ontvangers met bloedgroep A of B. Echter, na correctie in een 
multivariate analyse correleerde alleen nog het aantal sessies immunoadsorptie (IA) 
met het aantal postoperatieve bloedtransfusies. Het hemoglobinegehalte daalde tijdens 
desensibilisatie voorafgaand aan ABOi niertransplantatie met gemiddeld 0.55 mmol/L, 
hetgeen een factor was in de grotere bloedtransfusie behoefte. Daarnaast hadden ABOi 
ontvangers ook meer bloedverlies intra-operatief dan ABOc ontvangers (544 vs 355 ml). 
De  stollingstesten aPTT en PT-INR verschilden niet tussen ABOi en ABOc ontvangers. 
Het grotere bloedingsrisico zoals beschreven in hoofdstuk 4 werd ook gevalideerd in 
de meta-analyse in hoofdstuk 2, waarbij de techniek van immunoadsorptie versus 
plasmaferese geen factor bleek.
In hoofdstuk 5 lieten we zien dat bij het weglaten van postoperatieve 
immunoadsorptie (IA) de bloedgroep titers laag bleven en vergelijkbaar waren met 
het beleid van standaard drie postoperatieve IAs (de hoogste IgG titer binnen 2 weken 
na transplantatie was mediaan 4 versus 8 zonder postoperatieve IA (p=0.6)). Bovendien 
was er geen samenhang tussen het optreden van afstoting en de hoogte van de 
bloedgroep titers. ‘Rebound’ van A/B antistoffen kwam wel voor in ontvangers zonder 
postoperatieve IA, resulterend in IgG titers van 32 tot zelfs 128. Bij deze rebound trad 
er echter geen afstoting op. In de groep van 46 ontvangers zonder postoperatieve IA 
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hadden vijf een (gemengd cellulaire en) antistof-gemedieerde afstoting, van wie de 
postoperatieve IgG titers allen  ≤16 bleven.
In hoofdstuk 6 werden verschillende inductietherapieën binnen het nationale 
cohort van ABOi niertransplantatie ontvangers met elkaar vergeleken. Bij de 
beschreven 296 ABOi ontvangers werden  rituximab (n=146), rituximab/basiliximab 
(n=50) en alemtuzumab (n=92) het meest gebruikt als inductietherapie. Deze 
inductievergelijking was exploratief, dat wil zeggen niet gecorrigeerd voor mogelijke 
bias. Karakteristieken zoals transplantatiecentrum en jaar van transplantatie verschilden. 
De ontvangers behandeld met alemtuzumab waren ouder, terwijl de met rituximab 
behandelde ontvangers langer gedialyseerd hadden en minder frequent pre-emptief 
getransplanteerd werden. ABOi ontvangers behandeld met zowel de combinatie 
rituximab/basiliximab als met alemtuzumab inductie hadden niet-significant betere 
uitkomsten dan na inductie met alleen rituximab (HR voor transplantaat falen vergeleken 
met rituximab 0.32 [95%CI 0.04-2.45] respectievelijk 0.87 [95%CI 0.36-2.13]). De trend 
naar slechtere uitkomsten na (alleen) rituximab zou verklaard kunnen worden door 
meer afstoting: 47% rejectie in het eerste jaar na rituximab versus 22% na rituximab/
basiliximab versus 4% na alemuzumab inductie(p <0.001). De nierfunctie na 1 jaar was 
beter na zowel alemtuzumab als na rituximab/basiliximab vergeleken met rituximab 
inductie. De patiëntoverleving verschilde niet binnen de drie groepen. In tegenstelling 
tot de grote bijdrage van infecties aan overlijden in de meta-analyse in hoofdstuk 2, 
hadden binnen het nationale cohort maar 2 van de 18 gerapporteerde sterfgevallen 
(weliswaar binnen 5 jaar na niertransplantatie) een infectieuze doodsoorzaak. Geen 
van deze 2 infectieuze sterfgevallen waren bij ontvangers met gecombineerde T- en 
B-cel inductie.
In hoofdstuk 7 werd een ABOi niertransplantatie ontvanger beschreven die een 
fulminante antistof-gemedieerde afstoting doormaakte tijdens een Gram-negatieve 
sepsis. Haar anti-A titer steeg tot IgM >5000 en IgG 512. Het optreden van afstoting 
drie maanden na niertransplantatie in combinatie met de zeer hoge titers brachten 
ons tot de hypothese dat herkenning van bacteriële epitopen lijkend op bloedgroep A 
antigenen, tot ‘boostering’ van haar anti-A antistoffen geleid heeft. Een aantal publicaties 
ondersteunt deze booster hypothese: een bloeddonor die trombocyten doneerde had 
veel probiotica tot zich genomen, waarna ernstige hemolytische transfusiereacties 
optraden bij 2 patiënten die zijn trombocyten getransfundeerd hadden gekregen (3). 
Deze probiotica in opgeloste vorm bleken na incubatie met plasma de bloedgroep titers 
verlaagd te hebben. In de jaren 60 heeft Springer  volwassenen en kinderen opgeloste 
E. Coli bacteriën laten drinken en toonde aan dat hun anti-B titer hierop fors steeg (4). 
In experimenten beschreven in hoofdstuk 7 hebben we anti-A plasma geïncubeerd met 
Serratia marcescens. Door vervolgens A erythrocyten toe te voegen kon onderzocht 
worden of deze pre-incubatie met bacteriën de hemagglutinatie geremd had, wat helaas 
niet het geval bleek. In het supernatant waren er geen verschillen in titers. De booster 
hypothese werd dus niet ondersteund door onze experimenten.




Vergelijking ABOi met ABOc levende donor en ABOc overleden donor niertrans-
plantatie 
De meta-analyse in hoofdstuk 2 liet een iets slechtere patiënt- en transplantaat- 
overleving zien na ABOi dan na ABOc levende donor niertransplantatie (1-jaars 
transplantaatoverleving niet-gecorrigeerd voor overlijden 96% versus 98% (RR 0.97, 
95%CI 0.96-0.98). De meta-analyse over hetzelfde onderwerp een jaar later (Scurt et al.) 
liet slechtere uitkomsten zien na ABOi niertransplantatie dan onze analyse (5): 1-jaars 
patiëntoverleving van 96.9 versus 97.8% in ABOi versus ABOc (OR 2.17 [95%CI 1.63-
2.90] en transplantaatoverleving gecorrigeerd voor overlijden 95.8 versus 95.0% (OR 
2.52 [95% CI 1.8-3.54]). Deze studie is echter flink bekritiseerd vanwege het gebruik 
van odds ratio’s in plaats van relatieve risico’s en voor het includeren van overlappende 
patiëntenpopulaties, welke beide tot een overschatting van het verschil geleid hebben 
(6, 7). In tegenstelling tot onze meta-analyse, betrok Scurt et al. ook studies vòòr de 
introductie van rituximab, toen splenectomie ingezet werd om antistof ‘rebound’ te 
voorkomen. De ‘Supplemental Materials’ van Scurt et al. bevatte een subgroep analyse 
van de splenectomie versus de rituximab groep. De rituximab groep had een betere 
transplantaatoverleving gecorrigeerd voor overlijden met een OR van 1.72 [95%CI 1.01-
2.94] maar met nog steeds een slechtere patiëntoverleving vergeleken met ABOc met 
een OR van 1.97 [95%CI 1.14-3.42] (5). Deze data laten zien dat splenectomie voor 
ABOi niertransplantatie obsoleet is (8).  Ondanks dat in Nederland geen splenectomie 
toegepast werd, zijn de Nederlandse uitkomsten na ABOi zoals beschreven in hoofdstuk 
6 slechter dan de uitkomsten zoals beschreven in de meta-analyse in hoofdstuk 2 (1-
jaars transplantaatoverleving niet gecorrigeerd voor overlijden na ABOi in het nationale 
cohort 91.8%  versus 96% in de meta-analyse).  De nationale ABOc ‘gematchte’ 
controle ontvangers hadden óók slechtere uitkomsten dan in de meta-analyse (1-jaars 
transplantaatoverleving niet gecorrigeerd voor overlijden was 95.7% versus 98%). De 
fors hogere leeftijd van zowel donor als ontvanger van elk circa 10 jaar zal zeker een 
rol gespeeld hebben in de lagere patiëntoverleving in zowel de nationale ABOi als de 
nationale ABOc populatie. Een mogelijk bijdragende factor van de inferieure uitkomsten 
in het nationale cohort is het initiële gebruik van (alleen) rituximab inductie, aangezien 
er een trend onderscheiden kon worden naar een slechtere transplantaatoverleving 
voor rituximab versus zowel rituximab/basiliximab als alemtuzumab. Van de 26 studies 
waarop de meta-analyse gestoeld was, had alleen de studie die het ‘Zweedse protocol’ 
beschrijft, monotherapie rituximab als inductie (1). Behalve twee studies met ATG of 
met basiliximab (9, 10) betreffen de andere studies een regime waarbij rituximab 
gecombineerd werd met een T-cel gerichte inductie. Deze bevindingen pleiten voor 
de toegevoegde waarde van een (tevens) T-cel gerichte therapie bij  ABOi inductie zoals 
ook verderop in deze discussie beschreven wordt.
Ondanks een hogere mortaliteit in het eerste jaar na ABOi niertransplantatie dan na 
‘propensity-matched’ ABOc overleden donor niertransplantatie, is de patiëntoverleving 
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daarna beter (hoofdstuk 6). Dit komt overeen met een recente analyse van de 
Amerikaanse Scientific Registry of Transplant Recipients (SRTR). Massie et al. liet 
zien dat de overleving na ABOi niertransplantatie superieur was aan ‘gematchte’ 
wachtlijst kandidaten die een niertransplantatie ondergingen (merendeels van een 
overleden donor) dan wel nog op de wachtlijst hiervoor stonden, vanaf 180 dagen 
na niertransplantatie (11). Anders dan in deze studie, corrigeerden wij in hoofdstuk 6 
niet voor de sterfte die kan optreden bij wachtlijst kandidaten in de ‘survival analyse’. 
Deze ‘immortal time bias’ in hoofdstuk 6 wijst op een onderschatting van het gunstige 
effect van ABOi niertransplantatie ten opzichte van (wachten op) een overleden donor 
niertransplantatie. Wel hebben we een sensitiviteitsanalyse uitgevoerd op dialyse duur, 
welke een niet-significante betere patiëntoverleving liet zien na ABOi versus ABOc 
overleden donor niertransplantatie (HR voor overlijden 0.82 [95%CI 0.59-1.14].
De bevindingen van de meta-analyse en het nationale cohort bekrachtigen 
de keuze voor ABOi niertransplantatie in plaats van ABOc overleden donor 
niertransplantatie. Omdat de uitkomsten wel matiger zijn dan na ABOc levende donor 
niertransplantatie, zijn ze aanleiding tot het stimuleren van een uitgebreid levende 
donor niertransplantatieprogramma om de kans op een ABOc aanbod te vergroten. 
Tevens zijn deze bevindingen aanleiding tot het kritisch beoordelen van de onderdelen 
van desensibilisatie behandelingen, om de uitkomsten na ABOi niertransplantatie te 
verbeteren.
Antistof-gemedieerde afstoting
De resultaten beschreven in dit proefschrift laten zien dat antistof-gemedieerde 
afstoting een probleem is na ABOi niertransplantatie: in 11 van de 50 eerste ABOi 
ontvangers in het Erasmus MC trad antistof-gemedieerde afstoting (ABMR) op 
(hoofdstuk 3). Daarbij moet vermeld worden dat 9 van deze 11 afstotingen optraden in 
de eerste 25 ontvangers. Bloedgroep O ontvangers vormden de overgrote meerderheid 
(88%) van dit cohort. De hogere anti-A/B titers in bloedgroep O ontvangers vormen een 
risicofactor voor ABMR en benadelen de lange termijn transplantaatoverleving na ABO 
niertransplantatie (12-14). In het Nederlandse nationale cohort (hoofdstuk 6) hadden 
bloedgroep O ontvangers een niet-significante slechtere transplantaatoverleving. 
Het belang van de bloedgroep en de antistof titers van ontvangers zorgen ervoor dat 
als deze informatie ontbreekt, de externe validatie van vergelijkende studies binnen 
ABOi niertransplantatie kleiner wordt. Bij de meta-analyse in hoofdstuk 2 ontbrak 
bloedgroepinformatie echter en lag de focus op de vergelijking tussen ABOi en ABOc uit 
hetzelfde centrum. Wel liet de meta-analyse een hoger risico zien op ABMR na ABOi dan 
na ABOc levende donor niertransplantatie.  Aangezien panel reactieve antistoffen (PRA), 
donor specifieke antistoffen (DSA), retransplantatie en humaan leucocytenantigenen 
(HLA) mismatches vergelijkbaar waren met ABOc controle ontvangers uit hetzelfde 
centrum, leek het verhoogde ABMR risico te komen door de ABO incompatibiliteit 
en niet door ‘vaststaande’ patiënteigenschappen. Preoperatieve A/B titers zijn een 
risicofactor voor het optreden van ABMR en voor transplantaat verlies (13). Alle ABOi 
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desensibilisatie protocollen erkennen dan ook het belang van lage preoperatieve IgG 
A/B titers en definiëren streeftiters om te kunnen opereren. Een vergelijking van deze 
streeftiters tussen verschillende centra wordt echter bemoeilijkt door de verschillende 
testen die gebruikt worden om A/B titers te meten (15). De starttiter voorafgaand aan 
desensibilisatie en de direct preoperatieve titer lijken een grotere bijdrage te leveren aan 
het wel of niet optreden van accommodatie dan postoperatieve titerverlaging (16, 17). 
De studie in hoofdstuk 5 beschreef dat postoperatieve plasmaferese (immunoadsorptie) 
achterwege gelaten kan worden in ABOi ontvangers, mits de preoperatieve titers laag 
gehouden worden. Ook al zijn deze bevindingen overeenkomstig andere publicaties (18, 
19), Tobian et al. vond wel een correlatie tussen postoperatieve titers en het optreden 
van ABMR (20).
Het limiteren van (postoperatieve)  plasmaferese (immunoadsorptie) is belangrijk 
voor het vermijden van bloedtransfusie (hoofdstuk 2 en 4). Andere publicaties hebben 
ook deze bijdrage van plasmaferese aan bloedingsrisico beschreven (21). In ons centrum 
hebben we het aantal sessies immunoadsorptie kunnen beperken door het gewisselde 
plasmavolume te verhogen van 6 naar 12 liter (ongepubliceerde data, mondelinge 
communicatie dr Van Agteren). Naast ‘rebound’, kan accommodatie ook teniet gedaan 
worden door ‘boostering’ van antistof productie. Hoofdstuk 7 beschreef een ontvanger 
met een late ABMR met hoge IgM en IgG titers en onderzocht of haar Gram-negatieve 
sepsis tot een ‘boostering’ van haar anti-A antistoffen geleid zou kunnen hebben. 
Alhoewel er beschreven is dat bacteriën A/B antistofproductie kunnen ‘boosteren’ (3, 
4), resulteerde het kweken van Serratia marcescens met anti-A plasma niet in een anti-A 
titer verandering van dit plasma. Er zijn weinig publicaties over ABMR tijdens sepsis na 
ABOi niertransplantatie. De theorie van de ‘accommodatiebreuk’ door bacteriëmie 
speelt in de dagelijkse praktijk waarschijnlijk geen grote rol.
Accommodatie en het vermijden van ABMR zijn dus zeer relevant voor ABOi 
niertransplantatie, waarbij het frequenter optreden van ABMR waarschijnlijk bijdraagt 
aan de hogere sterfte zoals beschreven in de meta-analyse.
Inductie therapie
Bij desensibilisatie is naast het verwijderen van de aanwezige antistoffen door middel 
van plasmaferese, ook het remmen van antistof productie middels inductietherapie van 
belang. Rituximab heeft splenectomie vervangen en is een onderdeel van de inductie 
in de overgrote meerderheid van de desensibilisatie protocollen. De Opelz registratie 
liet een niet-significant slechtere transplantaatoverleving zien bij desensibilisatie 
zonder rituximab (22). Over de dosis wordt gediscussieerd in de literatuur, maar het 
gebruik op zich van rituximab is alomtegenwoordig (23). De retrospectieve analyse 
in hoofdstuk 6 beschreef een relatief groot cohort van ABOi ontvangers behandeld 
met alemtuzumab (n=92). ATG wordt in de Verenigde Staten vaak gebruikt in plaats 
van rituximab (9), en de combinatie ATG/ rituximab is toegepast in Frankrijk (24). Er 
bestaan geen gerandomiseerd-gecontroleerde studies die rituximab in het kader 
van ABOi vergelijken met andere inductiestrategieën.  Aangezien zowel ABMR als 
10
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infectie vaker optraden (hoofdstuk 2), is de opgave voor ABOi niertransplantatie om 
inductietherapie toe te passen die voorkomt dat therapie tegen afstoting nodig is, en die 
op hetzelfde moment de infectiedruk laag houdt. De ‘3C studie’ vergeleek alemtuzumab 
met basiliximab inductie in ABO-compatibele niertransplantatie ontvangers en liet 
zien dat het verminderen van rejectie haalbaar is terwijl het aantal infecties gelijk 
bleef (25). In deze studie gaf alemtuzumab een 58% proportionele reductie in biopsie 
bewezen acute afstotingen vergeleken met basiliximab, met ernstige infecties die bij 
32% van de ontvangers in beide groepen optraden. In onze nationale studie resulteerde 
alemtuzumab in opvallend weinig afstotingen: slechts 4% van de alemtuzumab  versus 
47% van de rituximab versus 22% van de rituximab/ basiliximab ontvangers werden 
behandeld voor afstoting in het eerste jaar (p <0.001, hoofdstuk 6). 
Het is dan ook hoog tijd voor een inductiestudie in ABOi niertransplantatie, waarbij 




Imlifidase is een nieuw desensibilisatie medicijn en afkomstig van een enzym 
van Streptococcus pyogenes dat IgG afbreekt. Het lijkt veelbelovend voor HLA-
incompatibele niertransplantatie door de snelle en volledige afbraak van IgG in bloed 
en weefsel  binnen enkele uren (26). Nieuw IgG kwam na zeven tot 14 dagen terug. 
Dit roept de vraag op of dit ‘IgG klievende’ enzym ook ingezet kan worden voor ABOi 
niertransplantatie. Een belangrijke hindernis is dat imlifidase geen IgM ‘klieft’. IgM A/B 
titers hebben enigszins een correlatie met IgG titers, en hoe relevant IgM titers zijn voor 
ABOi niertransplantatie is eigenlijk nog niet duidelijk. Tierney et al. beschreef zeven 
A2 levende donor niertransplantatie ontvangers in niet-geïmmuniseerde bloedgroep 
O ontvangers (PRA 0%) met een IgG titer <8 die behandeld werden met depleterende 
inductie maar zonder desensibilisatie/ plasmaferese (27). Vier ontvangers hadden 
opvallend hoge IgM titers tussen de 32 en 128, van wie drie een ernstige afstoting 
doormaakten. Andere publicaties wijzen ook op de relevantie van IgM anti-bloedgroep 
antistoffen voor ABMR na ABOi niertransplantatie, hetgeen anders is dan IgM anti-HLA 
antistoffen, die niet relevant lijken voor ABMR in (ABOc) niertransplantatie (28). Dit in 
ogenschouw nemende zou imlifidase in eerste instantie alleen bij lage IgM A/B titers 
ingezet kunnen worden. 
Accommodatie
Een andere aanpak in de preventie van ABMR na ABOi niertransplantatie zou het 
verminderen van de antigeniciteit van de ABOi donornier kunnen zijn. Tanabe et 
al. onderzocht bloedgroep antigen expressie in nierbiopsieën door middel van 
immunohistochemie in zes ABOi niertransplantatie ontvangers (29). Deze expressie nam 
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af tot een niveau van 64% op jaar 10 ten opzichte van implantatie biopsieën. In protocol 
biopsieën van ABOc ontvangers bleef de bloedgroep antigen expressie met 99.8% op 
hetzelfde niveau na dezelfde follow-up. Er zijn verschillende (theoretische) opties die 
de interactie tussen A/B antistoffen en A/B antigenen zouden kunnen remmen: het 
verminderen van A/B antigen expressie door recombinant galactosidase enzym te 
infunderen (30) of het neutraliseren van A/B antistoffen (31). Alhoewel veelbelovend 
in in vitro experimenten, zijn deze opties nog niet toegepast in klinische studies.
Prioritering programma’s voor ABO-incompatibele niertransplantatie kandidaten
Voor een niertransplantatie kandidaat met een beoogde ABOi donor, is het Nederlandse 
beleid om dit ABOi koppel te laten participeren in de nationale cross-over; in het 
algemeen voor 2 rondes (6 maanden). Het succes van dit beleid is echter beperkt: 
van de 48 ABOi niertransplantatie kandidaten in dit programma in 2018, ontvingen 
slechts acht een ABOc cross-over donornier, ondergingen 11 (desensibilisatie voor een) 
ABOi niertransplantatie en werden zeven mensen getransplanteerd met een ABOc 
donor nier buiten de cross-over (32). Om de cross-over kansen voor ABOi kandidaten 
te verbeteren, kan ofwel de pool (dus het programma) uitgebreid worden of kunnen 
de allocatie regels aangepast worden ten faveure van ABOi kandidaten.  Het eerste 
kan bereikt worden door te stimuleren dat ook ABOc koppels vrijwillig meedoen in de 
nationale cross-over en door anonieme (‘non-directed’) nierdonatie (33). De tweede 
optie, aangepaste allocatie, werd gesimuleerd  in een computer gestuurde allocatie die 
prioriteit gaf aan geïmmuniseerde en bloedgroep incompatibele ontvangers (34): van de 
90 daadwerkelijk uitgevoerde niertransplantaties waren er 16 ABOi, terwijl computer-
allocatie resulteerde in 95 transplantaties, waarvan slechts 5 ABOi.  Bloedgroep 
incompatibiliteit kon dus in de meerderheid van de gesimuleerde transplantaties 
vermeden worden.
Het toestaan van A2-incompatibele overleden donor niertransplantatie
Een niertransplantatie kandidaat zonder een levende donor is aangewezen op overleden 
donor programma’s (35). In de Verenigde Staten zijn de regels voor allocatie in 2014 zo 
gewijzigd dat nieren van een overleden donor met A2(B) gealloceerd kunnen worden aan 
bloedgroep B ontvangers met lage anti-A titers (IgG ≤4) (36). Een retrospectieve analyse 
van de United Network for Organ Sharing (UNOS) database liet voor 560 A2-incompatibele 
niertransplantaties vergelijkbare uitkomsten zien als voor ABOc niertransplantaties (37). 
Een studie in het Verenigd Koninkrijk simuleerde overleden donor A2-incompatibele 
nierdonatie hetgeen resulteerde in meer niertransplantaties met 0-0-0 HLA mismatches 
en een kortere wachttijd voor bloedgroep B ontvangers (38).
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De studies in dit proefschrift hebben desensibilisatie behandeling voor ABO-
incompatibele niertransplantatie onderzocht. De bevindingen hebben de volgende 
klinische implicaties:
- Investeer in een uitgebreid levende donor niertransplantatieprogramma om de 
kansen op een ABO-compatibele donornier van een levende donor te vergroten 
(hoofdstuk 2 en 6).
- Indien er geen ABOc nier van een levende donor beschikbaar is, en wel een ABOi 
donor, transplanteer dan ABOi met een levende donor in plaats van (te wachten 
op) een overleden donor niertransplantatie (hoofdstuk 6).
- Wees bedacht op een hoger bloedingsrisico in ABOi ontvangers (hoofdstuk 2 en 4). 
De desensibilisatie behandeling resulteert in een hemoglobine daling van gemiddeld 
0.55 mmol/L en meer intra-operatief bloedverlies (hoofdstuk 4).
- Pas geen postoperatieve immunoadsorptie toe (hoofdstuk 5).
- Het hogere risico op (antistof-gemedieerde) afstoting moet betrokken worden in 
de keuze van de inductietherapie (hoofdstuk 3 en 6). Gecombineerde T- en B-cel 
gerichte inductietherapie lijkt betere resultaten te geven dan rituximab alleen.
- Bij vergelijkende studies binnen ABOi niertransplantatie moet de bloedgroep van 
de ontvangers vermeld worden (O versus non-O) (hoofdstuk 3 en 6).
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BUN blood urea nitrogen
cfu colony forming units
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pre-op preoperative
PT-INR prothrombin time-international normalized ratio
RR relative risk
RTX rituximab
S. marcescens Serratia marcescens
SD standard deviation
SEM standard error of the mean
SRTR Scientific Registry of Transplant Recipients
UNOS United Network for Organ Sharing
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31-01-2020 Transplantatie Symposium 2020 0.30
28-01-2020 Masterclass Critical Care Nephrology 0.20
14-11-2019 Kinisch Review Symposium 2019 0.20
15-09-2019 ESOT 2019: Europeans Society of Organ Transplantation  
(1 oral, 2 posters)
0.85
29-08-2019 Erasmus MC - Scientific Integrity 0.30
13-03-2019 Bootcongres 2019 Wetenschappelijk voorjaarscongres NTV  
(4 orals)
0.45
18-01-2019 BROK herregistratie 0.25
15-11-2018 Klinisch Review Symposium 2018 0.15
04-06-2018 ATC 2018: American Transplant Congress (1 oral) 0.65
15-03-2018 Joint NTV-BTS Transplantation Congress 2018 (1 poster) 0.40
08-02-2018 4e Regionale nascholing Nefrologie en Transplantatie anno 
2018: de huidige koers! (1 presentation)
0.30
18-01-2018 Transplantatie Symposium 2018 0.20
08-06-2017 Regionale nefro pathologie nascholing 0.05
02-04-2017 ATC 2017: American Transplant Congress 0.85
08-03-2017 Bootcongres 2017 Wetenschappelijk voorjaarscongres NTV  
(1 oral)
0.35
14-12-2016 Workshop Nefrologie Papendal 0.20
24-11-2016 Masterclass Kidney Transplantation Padua 0.50
06-10-2016 Transmurale Transplantatiezorg 0.15
09-03-2016 Bootcongres 2016 Wetenschappelijk voorjaarscongres 0.35
04-02-2016 3de Regionale nascholing: Niertransplantatie anno 2016: 
nieuwe inzichten en uitdagingen!
0.25
01-01-2016 Journal Club Internal Medicine 1.00
19-11-2015 Klinisch Review Symposium 2015 0.20
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13-09-2015 ESOT 2015: Europeans Society of Organ Transplantation  
(1 oral)
0.85
25-06-2015 Regionale Nierbiopsie Avond 0.10
11-03-2015 Bootcongres 2015 Joint NTV/ BTS Congres 0.55
13-11-2014 Erasmus MC – BROK (Basic course Rules and Organisation for 
Clinical researchers)
1.50
17-10-2014 ESOT + AST joint meeting: personalizing transplantation: from 
new diagnostics to new therapeutics
0.55
11-09-2014 Praktische Nefropathologie 0.45
03-04-2014 Masterclass in Kidney Transplantation Antwerp 0.50
26-03-2014 Bootcongres 2014 wetenschappelijk voorjaarscongres NTV  
(1 oral)
0.50
20-03-2014 Sixth Rotterdam Course in Electrolyte and Acid-Base 
disorders
0.20
01-01-2014 Teaching master students, nurses (in training), fellows internal 
medicine and nephrology
72.0
01-01-2014 Organizer minor: Solid Organ Transplantation 20.00
CURRICULUM VITAE
Annelies de Weerd werd op 8 februari 1979 geboren te Rotterdam. In 1997 behaalde 
zij haar VWO-diploma aan het Marnix Gymnasium in Rotterdam. Na het behalen 
van haar propedeuse Rechten aan de Vrije Universiteit Amsterdam in 1998, begon 
zij datzelfde jaar aan de studie Geneeskunde, eveneens aan de Vrije Universiteit. 
Met het afstudeerprofiel Immunologie en Ontstekingsprocessen behaalde zij cum 
laude haar artsexamen in 2004. Zij startte als arts-assistent op de afdeling Inwendige 
Geneeskunde in het Ikazia Ziekenhuis, alwaar zij in 2005 haar opleiding tot internist 
aanving (opleiders dr. A. Dees, Prof. dr. H.A.P. Pols en Prof. dr. J.L.C.M. van Saase). In 
2008 heeft zij gedurende een jaar haar opleiding onderbroken om onderzoek te kunnen 
doen op het Transplantatie Laboratorium in het Erasmus MC (supervisoren Prof. dr. 
C.C. Baan en Prof. dr. W. Weimar). In 2011 startte zij met haar differentiatie Nefrologie 
(opleider Prof. dr. R. Zietse). Vanaf december 2013 is zij werkzaam als internist-nefroloog 
in het Erasmus MC. Het onderzoek wat zij de afgelopen jaren gedaan heeft naar ABO-
incompatibele niertransplantatie (supervisoren Prof. dr. R. Zietse en dr. M.G.H. Betjes), 
heeft uiteindelijk geresulteerd in dit proefschrift.
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DANKWOORD
Het leuke van werken in een ziekenhuis is dat je zo ontzettend veel collega’s hebt. Dat 
geldt onverminderd voor het verrichten van klinisch onderzoek. Ik wil dan ook een grote 
groep mensen bedanken die mij dagelijks helpen en inspireren. 
Michiel, mijn copromotor: Het is niet zonder risico om jou één korte vraag te stellen 
over welk nefrologisch onderwerp dan ook. Na jouw vlammend wetenschappelijk 
betoog sta ik geïnspireerd, maar ook met drie nieuw uit te voeren plannen weer buiten. 
Je hebt een scherp oog voor het scheiden van zin en onzin: het door jou tot de essentie 
brengen heeft het werk altijd beter gemaakt. En niet onbelangrijk, je kan altijd gezellig 
ouwehoeren over elk niet-nefrologisch onderwerp.
Bob, behalve als mijn promotor, heb ik je ook mogen meemaken als opleider en 
sectorhoofd. Dit alles doe je met grote kundigheid waarbij je ook graag blijft dokteren: 
Jij stond vooraan in de rij voor Tattoo Bob klompen om de covidzorg te dragen.
De leden van de leescommissie wil ik bedanken voor het kritisch lezen van het 
manuscript. Marlies, vanaf de dag dat jij ons Rotterdamse team bent komen versterken 
voelt het goed dat zo’n aardige en professionele vrouw ons hoofd Transplantatie is. 
Ik kijk uit naar alle projecten die we gaan doen. Stefan, jouw bevlogenheid voor de 
nefrologie heeft me altijd geïnspireerd. Het voelt goed om je in den lande tegen te 
blijven komen. Teun, wat fijn je weer even in ons Rotterdamse midden te hebben!
De leden van de grote commissie, Frederike Bemelman, Luuk Hilbrands, Robert Minnee 
en Peter Te Boekhorst, wil ik hartelijk danken voor het plaatsnemen in de oppositie.
Madelon, jij hebt het ABO-incompatibele niertransplantatieprogramma opgezet in 
Rotterdam, aangespoord door Willem Weimar. En nog steeds als  er gedesensibiliseerd 
moet worden, zijn de ogen op jou gericht als plasmaferese, immunoadsorptie en 
hemodialyse in serie geknutseld moeten worden.
Ik wil alle co-auteurs van de verschillende hoofdstukken bedanken.
Marije, Margriet en Jan: Wat is het leuk om met collega’s in den lande samen te 
werken aan nationale data. We zijn inmiddels vier baby’s en zes afwijzingen verder 
maar publicatie komt in zicht! 
Naast mij staan twee goede mannen: 
Martijn, jij bent in alles mijn tegenpool en je zult je wel groen en geel ergeren aan 
mijn niet zo clean-desk policy en mijn amodieuze verstandhouding met ICT. Je bent een 
geweldige, zeer collegiale collega.
Mijn grote neefje Ard. Als paranimf zal je beter over mij waken dan vice versa op een 
ochtend lang geleden in diergaarde Blijdorp. Als kleuter ontsnapte je aan het wakende 
oog  van je tante in de grote speeltuin. Hoe blij was ik je terug te vinden in die enorme 
glijbaan en weer samen veilig thuis te zijn toen die middag Bokito door de diergaarde 
struinde. Het ontroert me dat jij hier staat Ard.
Ik wil mijn collega-nefrologen Ewout, David, Dennis, Jacqueline, Joke en Marcia,  en 
de nefrologen-in-opleiding bedanken voor de goede samenwerking. In deze dank wil 
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ik ook de transplantatiechirurgen betrekken en in het bijzonder Diederik en Robert en 
de verpleegkundig specialisten Kelly en Erika.
Carla en de collega’s van het transplantatielaboratorium wil ik bedanken voor de 
samenwerking bij studies, maar ook voor mijn tijd in het laboratorium in 2008, waarna 
ik de knoop definitief doorhakte nefroloog te willen worden.
De Verpleegkundig Specialisten Louise, Marleen, Mireille en Mirjam: Een 
feestcommissie is niet compleet zonder jullie, en ook op de werkvloer is het fijn 
samenwerken: Marleen, met jouw goede humeur en dito mensenkennis doe ik graag 
samen poli.
De research verpleegkundigen wil ik bedanken voor de fijne samenwerking, de hulp 
bij de TACmono studie en Marieken voor de uitwisseling van boeken (en huisjes!).
De polidames, Judith, de transplantatiecoördinatoren, Saida, de verpleging van de 
dialyse en van de afdeling wil ik danken voor hun goede zorgen voor (ABO-incompatibele 
niertransplantatie) patiënten.
Pap en mam, gelukkig is de liefde te vanzelfsprekend om hier lang bij stil te staan. 
Liever roem ik op deze plek jullie wijsheid en plezier in kennis. Jullie hebben ons drieën 
enorm veel meegegeven, waardoor je zelfs bij groot verdriet nog houvast voelt. En 
mam, wat was het leuk om als drie generaties vrouwen naar congres in Brussel te gaan. 
Mijn samenvatting zou nog vol anglicismen staan zonder jouw inbreng, pap.
Opgroeien met twee oudere broers heeft zo zijn voordelen. Als een soort Leontine 
de bordjes omdraaien in een leuk jurkje bij Frank’s lekenpraatje was mijn kennismaking 
met de wetenschap. En vergeleken met chronisch spijbelende broer Peter kon ik wel 
een potje breken op de middelbare school. Hoe knap Peter dat je, met als wapen je 
goede pen, zo’n  florerende ondernemer geworden bent. En ook al heb ik honderd 
verjaardagen bij jullie meegemaakt, ik blijf me verbazen hoeveel kinderen er in jullie 
huis passen en hoe lekker je te midden van die chaos blijft koken. 
Mijn schoonouders Gerda en John: “There’s no place like home except for 
grandma’s”. Jullie verrijken ons leven met muziek, een gezellig glaasje wijn en jullie 
goede zorgen. Ik wil John bedanken voor het secure redactiewerk waarvoor hij de halve 
kerstvakantie aan de computer gekluisterd was. 
Lieve Jonah, Elaine en Sanne: Meegroeien met jullie kleine rituelen en grootse 
avonturen is een enorme rijkdom. De overdracht is steeds vaker van jullie naar ons en 
dat is maar goed ook! Hoe had ik anders kunnen weten dat ‘Wie is de mol?’ geen stom 
programma is, maar een goede aanleiding voor slaapfeestjes met veel cola en nog meer 
popcorn; dat je Alicia Keys heel goed kunt combineren met de Matthäus-Passion; en dat 
je met een tandenborstel en rietje prachtige schilderijen kan maken?
Pieter: grote liefde met een kleine bijdrage aan de letter van dit proefschrift, maar 
de grootste bijdrage aan alles van waarde er omheen: Ik ben je zo dankbaar voor ons 
leven samen. Ik verheug me enorm op een wandeling over de kliffen van Yorkshire, 
eindigend in de pub met een pint (of bitter, jij, en ik -hoe kansloos- shandy). 
Let’s have great fun!
AnneliesdeWeerd_bnw.indd   177 8-2-2021   10:34:35










AnneliesdeWeerd_OMS_V2.indd   2-3 8-2-2021   10:25:45
